Stockwinners Market Radar for July 06, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 268.7K shares of TuSimple today

20:07 EDT Cathie Wood's ARK Investment bought 129.5K shares of Block today

20:06 EDT Cathie Wood's ARK Investment bought 241K shares of Coinbase today

18:47 EDT LGI Homes reports 627 homes closed in June - LGI Homes "announced it closed 627 homes in June 2022, resulting in a total of 2,027 homes closed during the second quarter of 2022. As of June 30, 2022, the Company had 92 active selling communities."

17:34 EDT Volaris reports June traffic results up 11% year-over-year - Volaris reports June 2022 preliminary traffic results. Capacity - measured in ASMs - increased 17.2% vs. June 2021, while demand - measured in RPMs - increased 10.9% vs. the same period; the result was a load factor of 84.4%, -4.7 pp YoY. Volaris transported 2.4 million passengers during the month, a 10.4% increase vs. June 2021. Passenger demand - RPMs - in the domestic Mexican and international markets increased 9.9% and 13.5%, respectively, vs. June 2021. Year-to-date, Volaris' demand in RPMs increased 34.5% YoY, with a load factor expansion of 1.1 pp, to 84.0%.

17:13 EDT DiaMedica Therapeutics down 38% to $1.25 after placing DM199 on clinical hold

17:02 EDT China Green removed from NYSE late filers list following quarterly report - China Green announced that the company received a notice letter from the NYSE stating that, effective July 5, the company will be removed from NYSE's late filers' list to be disseminated to data vendors and will not be posted on the NYSE's Listed Standards Filing Status page. The NYSE's letter comes after the company filed its quarterly report on Form 10-Q for the period ended March 31, thus becoming current on its financial reporting obligations.

17:00 EDT DiaMedica Therapeutics trading resumes

16:49 EDT DiaMedica Therapeutics to resume trading at 17:00ET

16:38 EDT Crescent Point Energy raises quarterly dividend to 8c per share from 5c - The Company's Board of Directors has approved and declared a third quarter 2022 base dividend increase to $0.08 per share to be paid on October 3, 2022 to shareholders of record on September 15, 2022.

16:36 EDT Veru jumps another 17% after Jefferies predicts FDA authorization - Shares of Veru, which rallied 13% during the trading day to $13.02, jumped another 17% in after-hours trading to $15.39 after Jefferies predicted this morning's COVID-19 data would lead to an Emergency Use Authorization by the FDA in 30 days. Despite recent investor skepticism, the Phase 3 COVID-19 results for sabizabulin published this morning in the New England Journal of Medicine "addressed most concerns," Jefferies analyst Chris Howerton told investors in a research note. He reiterated a Buy rating on the shares with a $55 price target.

16:34 EDT DiaMedica says FDA puts clinical hold on Phase 2/3 ReMEDy2 trial - DiaMedica Therapeutics announced that the U.S. Food and Drug Administration has placed a clinical hold on the company's Phase 2/3 ReMEDy2 trial studying the use of the company's product candidate, DM199, to treat acute ischemic stroke patients. The clinical hold was initiated following the company's pause in patient enrollment and submission of three serious adverse event reports to the FDA related to clinically significant, transient hypotension occurring shortly after initiation of the intravenous dose of DM199. The blood pressure levels of the three patients recovered back to their baseline blood pressure within minutes after IV infusion was stopped. The company believes that the adverse events resulted from switching to an IV bag formulated from different materials in the ReMEDy2 trial compared to the IV bag used in the prior Phase 2 ReMEDy1 trial. Due to supply issues, the type of IV bag used in the ReMEDy1 trial was not available in many U.S. hospitals, and accordingly after routine compatibility testing, a different type of IV bag was selected for use in the ReMEDy2 trial. As part of the Company's evaluation of the events that lead to these hypotensive events, the Company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences. The company notes that no such hypotension issues were reported in its ReMEDy1 trial in which 46 stroke patients received DM199. The company may not enroll any additional patients in the ReMEDy2 trial until the company provides the FDA with the company's analysis of the events leading to or causing the hypotension, its suggested protocol modifications to address the mitigation of these events, its rationale and supporting data for the protocol modifications, and the FDA notifies the company that it may resume enrollment in the clinical trial. Based on information received to date, DiaMedica believes that proportionate reductions in the DM199 dose level and IV infusion times will effectively mitigate the hypotension issue in ReMEDy2 patients. The company plans to submit a revised ReMEDy2 trial protocol with the supporting rationale and data to the FDA for review upon completion of its compatibility analysis.

16:31 EDT First Bancshares receives regulatory approval for Beach Bancorp merger - The First Bancshares announced that it has received all required regulatory approvals for the consummation of its proposed acquisition of Beach Bancorp, parent company of Beach Bank based in Fort Walton Beach, Florida. The proposed acquisition, originally announced on April 26, 2022, is anticipated to become effective on August 1, 2022, subject to the satisfaction of customary closing conditions and the approval of the transaction by BBI's shareholders at the special meeting of BBI shareholders on July 21, 2022. The proposed acquisition will deepen The First's presence in the Florida panhandle, while also providing an entry into the Tampa, Florida market. Upon the completion of the acquisition, Beach Bank will merge with and into The First Bank.

16:20 EDT Global Cord Blood obtains injunction order against Blue Ocean - Global Cord Blood announced that an injunction order previously obtained by the company on June 15 from the Grand Court of the Cayman Islands against Blue Ocean was officially issued by the Court on July 6. The Order provides, among other things, that: until further order of the Court, any resolution or resolutions that might be passed or purported to be passed at any extraordinary general meeting of the company to be held or purporting to be held on June 16 or other meeting held or purporting to be held shall not take effect and shall not be implemented, and Blue Ocean must not: rely or purport to rely upon any such Resolutions; and/or seek to convene or convene any extraordinary general meeting of the company or other meeting. There will be a further hearing in respect of the Order and other matters on July 13-15. The company cautions its shareholders and others considering trading its ordinary shares to remain alert to the risks related to the present proceedings. The company will provide investors with an update as and when it is appropriate to do so.

16:18 EDT CytomX Therapeutics to resume trading at 4:35 pm ET - CytomX Therapeutics is scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq.

16:16 EDT CytomX reports Arm A of praluzatamab ravtansine trial met primary endpoint - CytomX Therapeutics announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive, or HR+/human epidermal growth factor receptor 2, or HER2-non-amplified breast cancer Arm A met its primary efficacy endpoint of confirmed objective response rate, or ORR, of greater than 10% by central radiology review. Praluzatamab ravtansine is a DM4-conjugated, conditionally activated antibody-drug conjugate, or ADC, targeting CD166 and is wholly owned by CytomX. As of the data cutoff on May 13, 47 patients unselected for CD166 expression with advanced HR+/HER2-non-amplified breast cancer were evaluable for the primary efficacy endpoint. The ORR by central radiology review was 15%. Clinical benefit rate at 24 weeks by investigator, or CBR24, as defined in the protocol as any response or stable disease for 24 weeks, was 40%; median progression-free survival was 2.6 months. All patients in Arm A were treated at the initial Phase 2 starting dose of 7 mg/kg administered every three weeks. Arm B did not pass protocol-defined futility boundary in patients with advanced triple-negative breast cancer, or TNBC, and enrollment into Arms B and C will be discontinued. As of this data cut, the safety profile of praluzatamab ravtansine in Arm A was generally consistent with toxicities observed in Phase 1 and with the DM4 payload; namely, high-grade toxicities or toxicities resulting in dose modifications were predominantly ocular or neuropathic in nature. Thirty percent of patients discontinued treatment for an adverse event. Grade 3+ ocular and neuropathic toxicities were 15 and 10 percent, respectively. Arm B evaluated both 7 mg/kg and 6 mg/kg in patients with TNBC. The toxicity profile of 7 mg/kg starting dose was consistent with Arm A. In the 6 mg/kg cohort, no patients discontinued treatment for an AE and Grade 3+ ocular or neuropathic related events were lower at 3% and 0%, respectively. Biomarker analysis is ongoing. CytomX intends to submit data from this study for presentation at a medical conference in the second half of 2022.

16:11 EDT Babylon Holdings announces cost reduction actions to get to profitability - Babylon Holdings Limited announced that it plans to accelerate its path to profitability through revenue and cost efficiencies, in response to changing market conditions. These efficiencies are being implemented during Q3 2022, with the expected financial impact being predominantly from Q4 2022 onwards. As a result, Babylon is improving its Adjusted EBITDA guidance for FY 2022 from $(295) million or less to $(270) million or less, with forecasted monthly December 2022 Adjusted EBITDA of $(18) million or less. There is no change to Babylon's revenue guidance being $1.0 billion or greater for FY 2022.

16:10 EDT Avalo Therapeutics announces one-for-twelve reverse stock split - Avalo Therapeutics announced a one-for-twelve reverse stock split of the company's common stock, par value $0.001, which will be effective tomorrow, July 7. The company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on July 8 under the company's existing trading symbol. The company is implementing the reverse stock split as planned to increase the per share price of its common stock to regain compliance with the listing requirements of the Nasdaq Capital Market.

16:09 EDT Johnson Controls' president of Global Products Jeff Williams retiring - Johnson Controls announced that 38-year company veteran Jeff Williams is retiring and that a global search is underway for his successor. Williams started at Johnson Controls in 1984 as a sales account manager and spent more than 30 years in its automotive business before taking over as leader of its Global Products business in 2019.

16:04 EDT LightPath, QuantLR partner to develop free space quantum encryption system - LightPath announced that QuantLR, an Israeli-based Quantum technology company that enables global mass deployment of Quantum Cryptography, has chosen LightPath as its partner to develop a free space quantum encryption system. LightPath and QuantLR will join forces to develop a ground-to-satellite, ground-to-air, ground-to-ground, and satellite-to-satellite free space optical communication channels, which will be used for a generation of quantum encryption keys, enabling secure quantum communication, or QKD. It is intended that this project can then be further developed for use in high-rate data transmission, optical communication both between satellite and ground station, as well as satellite-to-satellite communications.

16:00 EDT CytomX Therapeutics trading halted, news pending

13:58 EDT General Motors reports China Q2 sales of over 480,000 vehicles - In the second quarter of this year, GM sold more than 480,000 vehicles at retail in China, the company announced. "In the face of repeated COVID-19 outbreaks, GM's brands have made every effort to ensure production and operations with strong resilience, and sales have rebounded steadily since May. The company's new energy products maintained a positive growth trend, with sales up 12.5% year-on-year... At the same time, GM is at full speed with its transformation towards platform innovators. Following the Cadillac LYRIQ, the pure electric models of the Buick and Chevrolet brands based on the Autoneng platform will also be officially unveiled in the second half of this year," GM stated. Reference Link

12:43 EDT FDA revises Emergency Use Authorization for Paxlovid - The U.S. Food and Drug Administration revised the Emergency Use Authorization, or EUA, for Paxlovid to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid. Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients, 12 years of age and older weighing at least 40 kilograms or about 88 pounds, with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death. "The FDA recognizes the important role pharmacists have played and continue to play in combatting this pandemic. Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of COVID-19," said Patrizia Cavazzoni, M.D., director for the FDA's Center for Drug Evaluation and Research. Reference Link

12:31 EDT SCWorx receives final court approval to settle lawsuits - SCWorx announced that it has received final court approval to settle both the securities class action and derivative action lawsuits which were commenced in 2020. The class action was consolidated under the caption Yannes v. SCWorx Corp. The settlement resolves all claims asserted against SCWorx and the other named defendant without any admission of liability or wrongdoing by the Company or any defendant. Under the terms of the class action agreement, the insurers for the Company and Marc Schessel will make a cash payment to the class plaintiffs and the Company will issue $600,000 worth of common stock to the class Plaintiffs, in exchange for which all parties will be released from all claims related to the securities class action litigation. In addition, the Company and the Director Defendants entered into a settlement with the shareholder derivative plaintiffs to settle the derivative litigation in which SCWorx was a nominal defendant. Under the terms of this agreement, the insurers for the Director Defendants will make a cash payment to legal counsel for the shareholder derivative Plaintiffs to cover their legal fees and the Company will adopt certain corporate governance reforms, including adopting resolutions to address corporate transparency, further enhancing board independence, further enhancement of the CFO position, amendment of the audit committee charters, revisions to nominating committee and compensation committee charter and other similar enhancements, and addressing company policies, within 60 days of court approval of the settlement. In exchange for which all parties will be released from all claims related to the derivative class action litigation. Some of these enhancements have already been achieved.

12:13 EDT Weave Communications names Erin Goodsell as chief legal officer - Weave (WEAV) announced that it has added Erin Goodsell to its executive team as Chief Legal Officer. Goodsell comes to Weave after serving as Director & Associate General Counsel at Qualtrics (XM) for nearly six years.

12:00 EDT International Seaways falls -11.8% - International Seaways is down -11.8%, or -$2.43 to $18.25.

12:00 EDT Frontline falls -13.1% - Frontline is down -13.1%, or -$1.16 to $7.68.

12:00 EDT Cano Health rises 16.0% - Cano Health is up 16.0%, or 77c to $5.58.

11:52 EDT Voyager Digital files voluntary petitions for Chapter 11 bankruptcy - Voyager Digital announced earlier that it has commenced a voluntary Chapter 11 process to "maximize value for all stakeholders." As part of this process, the company and its main operating subsidiaries filed voluntary petitions for reorganization under Chapter 11 in the U.S. Bankruptcy Court of the Southern District of New York. The company intends to seek recognition of the Chapter 11 case of Voyager in the Ontario Superior Court of Justice pursuant to the Companies' Creditors Arrangement Act. The proposed plan of reorganization would, upon implementation, resume account access and return value to customers. Under this plan, which is subject to change given ongoing discussions with other parties, and requires court approval, customers with crypto in their account(s) will receive in exchange a combination of the crypto in their account(s), proceeds from the 3AC recovery, common shares in the newly reorganized company, and Voyager tokens. The plan contemplates an opportunity for customers to elect the proportion of common equity and crypto they will receive, subject to certain maximum thresholds. Customers with USD deposits in their account(s) will receive access to those funds after a reconciliation and fraud prevention process is completed with Metropolitan Commercial Bank. The company continues to evaluate all strategic alternatives to maximize value for stakeholders. The company has over $110M of cash and owned crypto assets on hand, which will provide liquidity to support day-to-day operations during the Chapter 11 process, in addition to more than $350M of cash held in the For Benefit of Customers account at Metropolitan Commercial Bank. Voyager also has approximately $1.3B of crypto assets on its platform, plus claims against Three Arrows Capital of more than $650M. "This comprehensive reorganization is the best way to protect assets on the platform and maximize value for all stakeholders, including customers. Voyager's platform was built to empower investors by providing access to crypto asset trading with simplicity, speed, liquidity, and transparency. While I strongly believe in this future, the prolonged volatility and contagion in the crypto markets over the past few months, and the default of Three Arrows Capital on a loan from the company's subsidiary, Voyager Digital, LLC, require us to take deliberate and decisive action now. The chapter 11 process provides an efficient and equitable mechanism to maximize recovery," said Stephen Ehrlich, CEO of Voyager.

11:32 EDT Walmart's announces availability of InHome as add-on in Walmart+ - Walmart's InHome Delivery Service, which delivers groceries straight to your fridge, is now available as an optional add-on within Walmart+. What were previously two standalone memberships are joining forces to bring all delivery capabilities into a single, streamlined experience, allowing new and existing members to choose the membership plan that appeals the most to them based on the type of delivery service they want. Walmart is also launching InHome in several new markets including Miami, Tampa, Orlando, Dallas, Austin, San Jose and San Francisco, nearly doubling the footprint where this service is available. Members of Walmart+'s $12.95 a month/$98 a year program can now add unlimited fee-free and tip-free InHome delivery for an extra $7 a month or $40 per year. That is $138 annually for both, $10 less than previous annual pricing when Walmart+ and InHome were separate memberships. New customers who sign up for both services also get to enjoy the lower rate of the combined programs.

11:06 EDT T. Rowe Price appoints Lauren Bloom as head of Canada - T. Rowe Price announced that Lauren Bloom has been named head of Canada. Bloom is responsible for leading and executing T. Rowe Price's distribution business strategy in Canada. In her new role, she will report to Chris Newman, head of Americas distribution for the firm. Bloom was previously head of intermediary and defined contribution, Canada. Samantha Cleyn has been promoted to head of institutional for Canada. In this role she is responsible for developing and executing a business plan for serving institutional clients. Cleyn was previously head of Eastern Canada for T. Rowe Price's Americas division; this new position expands her responsibilities to the entire country. These promotions follow a strategic business and organizational review following the retirement of Bruce Winch, previously head of Canada for T. Rowe Price, who retired from the firm on March 1, 2022.

11:04 EDT Plug and Play's Travel & Hospitality program enters partnership with Sabre - Sabre Corporation announced its partnership with Plug and Play's Travel & Hospitality program headquartered in the heart of Silicon Valley. Through this partnership, Sabre will enhance its visibility and gain early access to the global startup community.

11:02 EDT Qualtrics launches 'Irreverent' film series on XM+ - Qualtrics announced the launch of "Irreverent", a new film series on XM+. "Irreverent" is available to all XM+ subscribers. Upcoming episodes will feature other brands like Taco Bell, Patagonia, Impossible, and Traeger. Later this year, Qualtrics will premiere a series of short films examining the future of work and the importance of putting the employee experience first in order to attract, hire, and retain talent, it said in a statement.

11:00 EDT Square Enix delays 'Forspoken' again to January 24, 2023 - Square Enix (SQNXF) said that upcoming role-playing game "Forspoken," which will be a PlayStation 5 (SONY) console exclusive, will be delayed to January 24, 2023. "All game elements are now complete, and development is in its final polishing phase," the game maker said. The Fly notes that "Forspoken" has been delayed a number of times, with previously announced release dates being May 24, 2022 and October 11, 2022. Reference Link

10:58 EDT Sony says 'God of War Ragnarok' to launch November 9 for PS4, PS5 - Sony said that upcoming PlayStation 4 and PlayStation 5 exclusive game "God of War Ragnarok" will officially launch on November 9, 2022. "We're thrilled be able to share our release date and the brand-new God of War Ragnarok - Father and Son CG Trailer with all the God of War fans who have been eagerly awaiting news," the company said. "We hope you've enjoyed a glimpse at some of the dangers Kratos and Atreus could find themselves up against as Ragnarok approaches." The game is a sequel to 2018's "God of War." Reference Link

10:34 EDT Sarissa to vote for Alkermes director slate, still seeks board seat - Sarissa Capital Management earlier today issued a statement on Alkermes regarding how it intends to vote at the upcoming annual meeting. Sarissa said in part: "Richard Pops, the CEO and Chairman of Alkermes, has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago. Despite Alkermes growing revenues in the last five years and having annual revenues exceeding $1 billion, Alkermes has consistently operated at a net loss. During the same period, Alkermes stock has declined nearly 60% and underperformed the IBB by approximately 130%. Based on conversations with CEO Pops and its experience to date with the Alkermes nomination and governance process, Sarissa believes that certain of the independent directors are uncomfortable making decisions that are not supported by, or that reflect criticism of, CEO Pops. Alex Denner and Richard Pops and others have had a number of conversations which we were hopeful would lead to a Sarissa representative working on the Alkermes board to create value for all shareholders. Unfortunately, Pops set forth a version of these conversations in the Alkermes' securities filings which is fraught with misleading statements, inaccuracies and material omissions...Sarissa believes that its support of the recently appointed directors combined with the decisions of long tenured directors Anstice and Dixon, to not stand for re-election, should create an environment in the board room that will enable the directors to do the right thing for shareholders even in the face of resistance from Pops...We believe Alkermes' shares are significantly undervalued and that we can help to unlock shareholder value with our representatives on the board. We are hopeful that the current board will agree with us. Therefore, we intend to vote 'for' the Alkermes slate of directors (which consists entirely of recently appointed directors) at the upcoming annual meeting. If, however, a Sarissa representative is not soon appointed to the Alkermes board, then we will take steps under Irish law to quickly call another shareholder meeting that seeks to selectively remove and replace certain board members with those that Sarissa believes will act in the best interest of shareholders."

10:08 EDT Sisecam Chemicals proposes to buy Sisecam Resources LP for $17.90 per unit - Sisecam Chemicals Resources LLC announced that i delivered a non-binding proposal to the board of directors of Sisecam Resource Partners LLC, the General Partner of Sisecam Resources LP, to acquire all of the outstanding common units, representing limited partner interests in the Issuer not already owned by SCR or its affiliates, in exchange for $17.90 per issued and outstanding publicly held common unit of the partnership, which represents the thirty day volume weighted average per share, as of July 5. "There can be no assurance that any discussions that may occur between SCR and the Issuer with respect to the Proposal will result in the entry into a definitive agreement concerning a transaction or, if such a definitive agreement is reached, will result in the consummation of the transaction contemplated in such definitive agreement," Sisecam Chemicals Resources LLC stated.

10:03 EDT Real Good Food launches Real Good Foods Perks Program - The Real Good Food Company announcedthe launch of their Real Good Foods Perks Program on the Stockperks app. Real Goods Foods shareholders who leverage the Stockperks app can redeem perks based upon four levels of shareholding. Perks include digital gift cards for Realgoodfoods.com, Visa Gift Cards to purchase Real Good Foods products at major retailers such as Wal-Mart, Costco, Target or Kroger, a selection of merchandise in the Real Good Foods shareholder store, and for the largest shareholders, a special "Real VIP Perk." The Real VIP Perk includes priority access to taste new Real Good Foods innovations, complimentary fresh-to-your-door monthly delivery of the company's amazing products, company merchandise, gift cards and more. Please visit the Stockperks app for more details on how to claim the Real Good perks.

10:02 EDT Ambipar Response to become publicly traded via HPX Corp. merger - Emergencia Participacoes announced that it has entered into a definitive business combination agreement with HPX Corp. (HPX). Upon closing of the Business Combination, Ambipar Emergency Response, a newly incorporated Cayman Islands exempted company that will hold the business of Emergencia Participacoes S.A., is expected to become publicly listed on the NYSE under the ticker symbol "AMBI." Ambipar Participacoes e Empreendimentos, currently the sole shareholder of Emergencia Participacoes S.A., will remain a majority shareholder of Ambipar Response with an approximate 50% equity stake in Ambipar Response following the closing of the Business Combination and assuming no redemptions from HPX's existing public shareholders, and up to 72% in case of total redemptions of HPX existing public shareholders. Founded in 1995 by Tercio Borlenghi Jr, Ambipar Response provides a wide range of emergency, environmental and industrial services to a diversified client base in logistics, chemical, oil and gas, mining and industrial sectors. Ambipar Response expects to earn net revenues of approximately R$1.7 billion in 2022 and EBITDA of R$436 million, equivalent to $325 million and $81.8 million, respectively, if translated by the current USD - BRL exchange rate of $1.00 - R$5.33. Headquartered in Sao Paulo, Brazil, Ambipar Response has a portfolio of over 10,000 customers with long-standing relationships in a variety of sectors and geographies, including North America, Europe, LatAm, and Brazil. Over the last two years, Ambipar Response has achieved significant growth, including in the North American market, and has identified significant opportunities for continued expansion in all geographies, with a particular focus in the United States. The business combination values Ambipar Response at an implied $581 million enterprise value and a pro forma equity value of approximately $798 million, assuming no redemptions. Ambipar Group will receive shares of HPX as consideration and the transaction is expected to provide Ambipar Response with at least $168 million in gross proceeds through committed PIPE subscriptions and non-redemption agreements by high-profile institutional investors and high net-worth individuals, including Opportunity, Constellation, XP and Ambipar Group. The proceeds will be used to accelerate Ambipar Response's organic and inorganic growth. In addition, Ambipar Group has agreed to a three-year lockup on its rollover shares and HPX's sponsor has agreed to a three-year lockup on its founder shares. Assuming a total capitalization of $415 million, with no redemptions from HPX Corp. shareholders, the economic ownership structure following the Business Combination is expected to be approximately: 50% Ambipar Group, 48% PIPE and HPX public shareholders, and 2% HPX sponsor. In connection with the Business Combination, Ambipar Response will adopt a dual-class share structure pursuant to which Ambipar Group will hold Class B ordinary shares, which provide 10 votes per share, but are otherwise identical to the Class A ordinary shares issued to all other shareholders in connection with the Business Combination. Upon completion of the Business Combination, Ambipar Group is expected to hold at least a majority of the voting rights in Ambipar Response. The Business Combination, which has been approved by the Board of Directors of Ambipar Group and HPX, is expected to close during the second half of 2022, subject to the approval of the shareholders of HPX and other customary closing conditions.

10:00 EDT DoorDash falls -8.8% - DoorDash is down -8.8%, or -$6.58 to $68.32.

10:00 EDT Rocket Companies rises 8.9% - Rocket Companies is up 8.9%, or 72c to $8.77.

10:00 EDT Resolute Forest rises 64.8% - Resolute Forest is up 64.8%, or $8.09 to $20.58.

09:49 EDT Alpine 4's RCA Commercial receives $2.5M in orders for first week in July - Alpine 4 Holdings' subsidiary RCA Commercial received orders for the first week of July totaling $2.5M. These orders equate to the company's largest weekly group of orders in RCA Commercial's history. The company is experiencing strong demand for many of its products, including its line of commercial TV's, advanced LED lighting systems, and hospitality-related products.

09:47 EDT Noah Holdings falls -6.9% - Noah Holdings is down -6.9%, or -$1.43 to $19.26.

09:47 EDT SIGNA Sports United rises 8.5% - SIGNA Sports United is up 8.5%, or 51c to $6.50.

09:47 EDT Resolute Forest rises 64.6% - Resolute Forest is up 64.6%, or $8.07 to $20.56.

09:41 EDT Gambling com Group Ltd trading halted, volatility trading pause

09:38 EDT Sotherly Hotels reports Q2 occupancy of 69.5% - Reports ADR $181.61 and RevPAR $125.05. "We're encouraged with these preliminary results for the second quarter, which reflect the Company's continued improvement in performance and the sustained recovery of the industry," commented Dave Folsom, the Company's President and Chief Executive Officer. "The second quarter's improvements were largely driven by a strong return in demand from the business and group segments, which was layered with the continued strength in leisure demand."

09:34 EDT Manchester United announces DXC as digital transformation partner - Manchester United (MANU) confirmed a multi-year global partnership with DXC Technology (DXC), which will see the two organisations work together to enhance its digital offering to fans. DXC will use its expertise in digital transformation to improve the way United engages with fans through its digital platforms, including manutd.com and the Manchester United App by harnessing the power of data and analytics technologies. From the 2022/23 season, DXC will be visible on the club's home, away and third kits, creating worldwide brand exposure for the global tech company. DXC will also become the Presenting Partner of Manchester United Foundation. The partnership will focus on how technology can have a positive impact on people, the environment, and society, working together to educate and inspire a new generation of STEM students, through digital workshops, programmes and in-person seminars.

09:33 EDT Cosmos Holdings to acquire LIFE NLB portfolio of bone health products - Cosmos Holdings announced that it has entered into an agreement to acquire LIFE NLB, Ltd.'s product portfolio, including Bone-Vio and Bone-X, related to bone health targeting the human gastrointestinal microbiome. The intestinal microbiome has been proposed as a new therapeutic target for osteoporosis. It is believed to contribute to the integrity of the intestinal barrier and mineral absorption, which is strongly correlated with bone mass. Changes in the intestinal microbiome has been shown to lead to changes in the expression of cytokines and growth factors that affect the immune, endocrine, vascular and nervous systems, which in turn affect the regulation of differentiation and/or the functioning of bone cells. LIFE NLB'S Bone-Vio product is a combination of calcium citrate, Vitamin D and prebiotics that target the microbiome. Bone-Vio is currently being evaluated in a clinical trial with results of the trial expected to be published in 2023.

09:28 EDT BK Technologies appoints Kyle Cerminara as chairman - BK Technologies Corporation announced that board member Kyle Cerminara has been named Chairman of the Board of Directors. Mr. Cerminara replaces Major General E. Gray Payne, who will remain a board member. Mr. Cerminara was appointed to the Board of Directors in July 2015 and served as Chairman from March 2017 until April 2020.

09:27 EDT American Acquisition's target Royalty Managment enters data center agreement - American Acquisition Opportunity's merger target company, Royalty Management Corporation, a sustainably-driven, cash flow-oriented, royalty investment and development company, announced that it has entered into a long-term agreement to facilitate the development and deployment of data servers utilizing excess capacity power infrastructure located on an idled and unused mining property. Located in rural Kentucky, RMC was able to structure a long-term lease agreement to bring new industry to rural Kentucky by utilizing unused infrastructure and property for the use of building and operating servers for data hosting solutions. As part of this agreement, Royalty Management Corporation will receive a revenue stream based on the amount of allocated power that is utilized by the counterparty at this site.

09:25 EDT BK Technologies appoints Scott Malmanger as interim CFO - BK Technologies announced that its Board of Directors has appointed Scott Malmanger as a consultant to serve as the Company's interim Chief Financial Officer effective July 1st, 2022, succeeding Bill Kelly who is retiring from the Company in accordance with his previously announced plans. Mr. Kelly has agreed to remain available to the Company in an advisory role to ensure a smooth transition. Malmanger most recently served as Chief Financial Officer of OneroRX, a provider of telepharmacy services, from October 2019 to October 2021.

09:23 EDT Micron releases annual Sustainability Report - Micron Technology released "Investing in the Future: Micron's 2022 Sustainability Report," underscoring the company's continued commitment to innovation, the environment, and our people and communities. Micron exceeded all targets associated with its credit facilities announced last year. These metrics included securing a 40% improvement in greenhouse gas intensity compared to 2018; ensuring 90% of the company's waste is recycled, reused or recovered; and achieving a Responsible Business Alliance average facility audit score of 193.2 out of a possible 200. Micron also made meaningful progress in its diversity, equality and inclusion commitments. The company achieved comprehensive global pay equity for all underrepresented groups, surpassed its goal to invest 3% of its cash investments with diverse financial institutions and grew its annual spend with diverse suppliers to $212 million.

09:22 EDT Carpenter Technology to increase base prices on specialty alloy portfolio - Carpenter Technology will increase base prices by an average of 12%-15% on new, non-contract orders across the majority of its premium products. The increases will be effective with new orders placed after July 5. All applicable surcharges will remain in effect.

09:21 EDT Nuvei selected as payment provider by WeCook in Canada - Nuvei has partnered with ready-to-eat meal delivery platform WeCook as it expands across Canada. WeCook is using Nuvei's payment technology platform and payment experts' support to run both its business-to-business and direct-to-consumer payment processing needs. Montreal-based WeCook delivered more than four million meals throughout Quebec and Ontario last year and it is set on becoming a nationwide direct-to-door meals provider by 2023.

09:19 EDT Blink Charging receives EV charging award from Illinois Region 1 council - Blink Charging has been awarded a cooperative purchasing agreement for EV charging equipment and network services from the Region 1 Planning Council in Northern Illinois. The Region 1 Planning Council is a special-purpose, regional government agency providing cross-jurisdictional, government-to-government collaborative planning across Northern Illinois. The contract for EV charging equipment and services for up to a 10-year term will enable members of R1's council of governments to participate under any of Blink's deployment models with favorable negotiated terms as awarded. The initial plan estimates for up to 700 charging stations to be installed over the term of the purchasing agreement.

09:18 EDT Riot Blockchain reports June production, provides operations update - Riot Blockchain (RIOT) announced production and operations update for June. In June 2022, Riot produced 421 Bitcoins (BTC), an increase of approximately 73% vs. June 2021 production of 243 BTC. As of June 30, 2022, Riot held approximately 6,654 BTC, all produced by the company's self-mining operations. In June 2022, Riot sold 300 Bitcoin, generating net proceeds of approximately $6.2M. Riot currently has a deployed fleet of 42,455 miners, with a hash rate capacity of 4.4 EH/s. Riot has begun transitioning all of its miners hosted at Coinmint's Massena, NY facility. The transition will consist of both a relocation of miners to the Company's Whinstone Facility and by way of a miner swap agreement which Riot has entered into with another Bitcoin mining counterparty. Approximately 5,700 miners are currently offline, and temporarily not counted in the deployed fleet figure. It is expected that the Company will ship the balance of its S19 miner fleet presently at Coinmint to Riot's Whinstone Facility in July. The company expects to further reduce its cost of production through lower power costs and by eliminating all third-party hosting fees on its hosted mining fleet. Since its last monthly update. Upon deployment of the staged miners, the Company expects to have a total of 48,779 miners deployed with a hash rate capacity of approximately 5.0 EH/s. By January 2023, Riot anticipates a total self-mining hash rate capacity of 12.5 EH/s, assuming full deployment of approximately 115,450 Antminer ASICs, but excluding any potential incremental productivity gains from the company's utilization of 200 MW of immersion-cooling infrastructure. Substantially all of company's self-mining fleet will consist of the latest generation S19 series miner model. In addition to the company's self-mining operations, Riot hosts approximately 200 MW of institutional Bitcoin mining clients.

09:16 EDT Seanergy Marine announces completion of United Maritime spin-off - Seanergy Maritime Holdings reported that it has completed the spin-off of its wholly-owned subsidiary, United Maritime Corporation, effective July 5, 2022. The Company's shareholders received one United share for every 118 shares of Seanergy held at the close of business on June 28, 2022. Fractional common shares of United were not distributed. Instead, the distribution agent will aggregate fractional common shares into whole shares, sell such whole shares in the open market at prevailing rates promptly and distribute the net cash proceeds from the sales pro rata to each holder who would otherwise have been entitled to receive fractional common shares in the distribution.

09:12 EDT Better Choice Company issues shareholder letter with mid-year update - Better Choice Company is issuing a letter to shareholders providing a mid-year update highlighting the Company's recent developments and updates. Recent Company Highlights: Halo Elevate is officially on shelf in more than 1,500 pet specialty stores, in part due to the Company's retail sales team growing from three to ten professionals. Launched an Augmented Reality Experience driven by QR code on the back of every Halo Elevate Bag Concurrent with the additional of new sales team members, the company has also launched a global marketing campaign titled "The World's Best Food for the World's Best Kids" in collaborating with Humanaut, the Company's creative agency. The campaign consists of a full suite of digital assets on YouTube, Instagram, Facebook and TikTok, generating more than 17 million impressions and 11 million video views in the first month. The Company has joined the Russell Microcap Index, effective June 27, 2022. "In our last shareholder letter, I said that we are incredibly excited for what was shaping up to be a breakout year in 2022. This still holds true today. We have continued to build on our record first quarter sales, developed and launched a multi-million dollar marketing campaign, promoted two key members of our team and have been added to the Russell Microcap Index, all in the month of June!" said Scott Lerner, CEO of Better Choice Company.

09:12 EDT Raytheon selects C3 AI to deliver next-generation AI/ML ops - C3 AI (AI) announced Raytheon Technologies(RTX) has selected the C3 AI Application Platform to deliver next-generation AI and machine learning capabilities for a ready-now solution for the U.S. Army's Tactical Intelligence Targeting Access Node program. The Raytheon Technologies team, led by Raytheon Intelligence & Space, is in competition to design TITAN to serve as the Army's underpinning solution to enable multi-domain operations. TITAN is a tactical ground station that finds and tracks threats to support long-range precision targeting, further advancing the Department of Defense's strategy for Joint Force C2 capabilities necessary to support U.S. national security interests. The C3 AI Application Platform will provide AI/ML model operations for best-of-breed third-party models across the TITAN enterprise, including both cloud and intermittently connected edge environments.

09:11 EDT Sintx Technologies acquires Technology Assessment and Transfer - SINTX Technologies announced the acquisition of Technology Assessment and Transfer, significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. TA&T, based in Maryland, is a nearly 40-year-old advanced ceramics business that specializes in developing and commercializing a broad array of innovative materials for defense, biomedical, and industrial applications. The company's technologies and products include 3D printing of ceramic medical devices and heat exchangers, chemical vapor infiltration and deposition of complex fiber-reinforced ceramic-matrix composites, and hot pressing of transparent armor and other technical ceramics. TA&T has a long track record of successfully winning research contracts and grants from the U.S. government and commercializing its innovative technologies.

09:10 EDT CleanSpark reports June Bitcoin production of 12.1 BTC per day - CleanSpark released its unaudited bitcoin production and operations update for the calendar year-to-date ending June 30. June monthly production was 339, calendar year-to-date production ending June 30 was 1863, total BTC holdings as of June 30 were 561, total BTC converted for operations and growth in June were 328. Currently deployed fleet of approximately 28,500 latest-generation bitcoin miners with a hashrate exceeding 2.8 EH/s. The company fully funded growth and operations through the sale of 328 bitcoins in June at an average of approximately $25,644 per BTC. Sales of BTC equated to proceeds of approximately $8.4M. June daily BTC production reached a high of 12.1.

09:09 EDT Piper Sandler to acquire investment banking firm DBO Partners in San Francisco - Piper Sandler announced that it has entered into a definitive agreement to acquire DBO Partners, an independent technology investment banking firm in the San Francisco Bay Area. The transaction is expected to close in the fourth quarter of 2022 and is subject to customary closing conditions

09:09 EDT Envestnet announces acquisition of Redi2 Technologies - Envestnet announced that it has acquired Redi2 Technologies, a leading provider of revenue management and hosted fee-billing solutions in the global financial services industry. The deal creates more connections across the Envestnet financial wellness ecosystem for asset managers, wealth managers, and registered investment advisors, RIAs. "Redi2 is a pioneer and innovator in the cloud-based delivery of wealth and investment management billing software, making them an ideal partner as we continue to strengthen our financial wellness ecosystem," said Tom Sipp, Executive Vice President of Business Lines for Envestnet. "With Redi2's solutions, we become the industry leading provider of revenue and billing tools needed by all industry constituents-including advisors, wealth firms, and asset managers. This acquisition enhances our strategic enablement of service and data, and over the next two years will create operating leverage by bringing Envestnet and Redi2's administrative, revenue, and billing services together."

09:07 EDT Surgalign's Holo Portal AI surgical guidance system used in Ohio - Surgalign reported that Selvon St. Clair, a board certified orthopaedic and spinal surgeon at the Orthopaedic Institute of Ohio, performed his first case with the HOLO Portal system. HOLO Portal is the world's first surgical guidance system to incorporate AI and AR.This is the first clinical application of Surgalign's HOLO AI digital health platform. In January, the company received FDA clearance for use of the HOLO Portal system within lumbar spine procedures. The company is currently expanding the system's limited market release and intends to ramp up its site locations throughout the year.

09:06 EDT Archdiocese of Seattle selects Pushpay's ParishStaq - Pushpay announces the Archdiocese of Seattle will be leveraging ParishStaq, the Company's fully integrated technology platform that helps parishes and dioceses increase engagement, facilitate digital discipleship, and grow their ministries.

09:05 EDT NXP Semiconductors announces specialized security algorithm for quantum threats - NXP Semiconductors announced that a specialized security algorithm co-authored by NXP security experts has been selected by NIST to become part of an industry global standard designed to counter quantum threats. A second algorithm co-authored by NXP will also advance to the fourth and final round for further analysis and consideration for standardization. As the dangers of quantum computers become more clear, this effort anticipates the need to protect encrypted data and connected devices. The selected post-quantum cryptography algorithms will be used to develop a new public key encryption standard that is secure against both traditional and quantum computers.

09:04 EDT Teladoc announces expanded capabilities for Primary360 - Teladoc Health announced expanded capabilities for Primary360 members to further remove barriers to access and increase convenience through one, seamless, comprehensive primary care experience that meets people where they are. Primary360 members will now receive health plan in-network referrals and care coordination support; free, same-day medication delivery from Capsule, the leading national digital pharmacy; and in-home, on-demand phlebotomy with Scarlet Health. Teladoc Health's primary care offering continues to gain market momentum, with Priority Health, a nationally recognized health plan, choosing Primary360 for its members this year.

09:00 EDT WISeKey, China Museum of Finance extend cooperation for digital museum - WISeKey International announced that it has extended its cooperation with The China Museum of Finance by creating the "MetaFi Museum," which is not only a digital museum, but also a physical museum. For the Inaugural launch of this cooperation, the WISe.ART platform will auction a historical NFT of the world's first paper money created in China in 1024. The China Museum of Finance is also preparing an NFT in cooperation with WISe.ART, the Gong silver dollar, minted by the Red Army in 1928. In particular, the unique historical significance of this silver dollar: the communist movement began in Europe and was always involved in the creation of the financial system.

08:56 EDT Enlivex Therapeutics doses first patient in Phase I/II cancer trial of Allocetra - Enlivex Therapeutics announced that the first patient has been dosed in a Phase I/II clinical trial evaluating Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancer. Preclinical studies suggest that Allocetra has the potential to synergistically combine with various anti-cancer agents to provide patients who do not respond well to existing FDA-approved therapies with an effective treatment option. The Phase I/II trial is designed to evaluate the safety and potential preliminary efficacy of Allocetra combined with SOC chemotherapy in patients with peritoneal metastases arising from solid cancer.

08:54 EDT U.S. Cellular to launch Siyata's SD7 device onto network - Siyata Mobile Inc. (SYTA) is pleased to announce that United States Cellular Corporation (USM) will launch Siyata's rugged SD7 device onto their network. We expect UScellular will commence selling the SD7 to their broad enterprise customer base beginning this quarter. The SD7 was developed to disrupt and replace the multi-billion-dollar Land Mobile Radio industry.

08:52 EDT RYAH Group announces issuance of failure-to-file cease trade order - RYAH GROUP announced The Ontario Securities Commission has issued a failure-to-file cease trade order on the trading of RYAH Group's subordinated voting shares listed on the Canadian Securities Exchange. This FFCTO is effective immediately. At the Company's request a management cease trade order was issued by the OSC on May 3, 2022. The Company expected that it would be in compliance with its continuous disclosure obligations before the end of the two-month period which terminated on July 4, 2022, as contemplated by National Policy 12-203 for a MCTO. Unfortunately, notwithstanding the best efforts of the new management and the Company's auditors, it was impossible to complete the needed work in time to meet the deadline. A key reason was that the previous management had not started the audit in a timely fashion. The Company's management and Board of Directors wish to inform its investors, partners, and service and goods suppliers that it will continue working diligently and rapidly to finalize the audit and to file the needed documents with the authorities. As par of its filing commitment, the Company will also need to file the March 31, 2022, quarterly financial statements, MD&A and CEO and CFO certificates. The Company's management and other insiders will continue to respect the insider trading prohibitions under securities legislation before entering into any transaction involving securities of the Company in default.

08:50 EDT Rigetti Computing announces chairperson transition - Rigetti Computing's Chairman of the board of directors Peter Pace will step down from his position. Director Cathy McCarthy has been appointed as Chair of the Board. Director Gail Sandford has been appointed to the Nominating and Corporate Governance Committee as well as the Audit Committee. All position changes will take effect as of July 15. McCarthy has served on Rigetti's Board since July 2021 and is currently President and CEO of the strategy consulting firm Cross Tack Consulting.

08:50 EDT DMG Blockchain Solutions granted crypto patent based on machine learning - DMG Blockchain Solutions announces the issuance of a patent by the US Patent and Trademark Office for U.S Patent No. S2020/0167791A1. This patent is for a novel method for detecting and tracking tainted cryptographic wallets in order to screen out nefarious actors. Generally, this technology can be applied to blockchains to support law enforcement's efforts to combat money laundering, terrorism and fraud. This patent describes methods for the underlying technology of Blockseer's Walletscore product, which is the basis for DMG's clean-block mining and can be used in mining pools. This technology allows Walletscore to automatically flag financially risky activities, enabling transaction requests to be monitored in real-time for further review - and potentially be removed - before committing them to the Blockchain. Walletscore can be used to screen out transactions originating from high-risk wallets, even if from several hops downstream from a known criminal occurrence. DMG plans to utilize this technology for future versions of its clean block mining offering.

08:48 EDT Eos Energy receives two orders for over 1 GWh - Eos Energy announced the signing of two orders with Bridgelink Commodities and a Northeast solar developer totaling 1.1 GWh of energy storage capacity to be delivered over the next three years. Bridgelink increased its multi-year master supply agreement to 1 GWh for deliveries over the next three years with an incremental order value of $181M for new project installations. In addition, Eos will manufacture a separate 40MWh order valued at $13M for Q4 delivery. Additionally, a 300 MWh MSA was signed with a Northeast solar developer for front of the meter stand-alone storage and solar plus storage applications that provide energy shifting and ancillary services with deliveries forecasted over the next three years.

08:47 EDT Cryptyde provides operational update, corporate objectives - Cryptyde announced its reporting of a corporate roadmap for the remainder of 2022 into 2023. Brian McFadden, President and CEO of Cryptyde, Inc. stated, "With our recent spinoff from Vinco Ventures, and now operating as a fully independent NASDAQ listed company, we wanted to provide an update regarding our business and forthcoming objectives to both our industry stakeholders as well as our investors. We believe that our accomplishments highlighted below have created a fundamental base for our organization to realize our stated objectives for 2022 carrying into 2023. We feel confident that upon successful execution, Cryptyde can become both an industry pioneer, as well as leader in the Web3 space. In addition, we are evaluating partnerships and business development opportunities that we believe should lead to acquisition candidates as part of our larger long-term growth strategy." Operational Achievements: Completion of the spinoff from Vinco Ventures, Inc.; Launch of Freescape Community - Freescape was featured in the Matter creator lounge at VidCon, where the world's leading digital creators, platform innovators and their fans converge in one place; Equity-based financing at a price of $8.00 per share; CW Machines continued delivery of BTC mining equipment to the resale marketplace/ Targeted H2 2022-H1 2023 Corporate Objectives: Focused growth on the transition from Web2 to Web3 in consumer facing industries; Launch of BTC Tokenization Platform to revolutionize consumer focused mining; Next launch phase of content driven Metaverse - Freescape; Diversification across multiple Web3 industries leveraging smart contract and tokenization technologies; Continued focus on creating shareholder value through strategic partnerships and acquisitions.

08:45 EDT Albireo Pharma's Bylvay meets primary endpoints in published study on PFIC - Albireo Pharma announced that The Lancet Gastroenterology & Hepatology published the results of the pivotal PEDFIC 1 trial, which evaluated Bylvay - odevixibat - for the treatment of progressive familial intrahepatic cholestasis, or . The study met both of its two primary endpoints, demonstrating that Bylvay provided statistically significant improvements in pruritus severity scores and reductions in serum bile acid levels, with rapid, sustained, and consistent results. Bylvay was recently approved in the U.S. for the treatment of pruritus in patients 3 months of age and older with all types of PFIC, and in Europe for the treatment of all types of PFIC in patients aged 6 months or older. The publication includes data from the randomized, double-blind, placebo-controlled Phase 3 PEDFIC 1 global study. The study also showed meaningful improvements in secondary endpoints related to pruritus and serum bile acids, with a greater proportion of patients treated with Bylvay having a clinically meaningful improvement in pruritus at week 24. In the study, Bylvay was well tolerated, with an overall adverse event incidence similar to placebo. Patients with PFIC have impaired bile flow, or cholestasis, and the resulting bile build-up in liver cells causes liver disease and symptoms including intense itching, poor sleep, delayed growth and diminished quality of life. The ASSERT study in Alagille syndrome is fully enrolled and topline data is expected by the end of the year. The BOLD study in biliary atresia is expected to complete enrollment this year with topline data available in 2024.

08:43 EDT Edible Garden reports on Zero-Waste Inspired ESG/Sustainability mandate - Edible Garden provided an update the success of its Zero-Waste Inspired ESG/Sustainability mandate. Jim Kras, CEO of Edible Garden, commented, "We are both pleased and proud to announce the positive impact of our Zero-Waste Inspired ESG/Sustainability mandate. As part of our involvement with Walmart Project Gigaton, an initiative with a goal of eliminating one billon metric tons, or one gigaton, of CO2 emissions from global value chains by 2030, it is estimated that during 2021, we contributed to the effort by saving 21,000 gallons of gasoline, recycling 38,000 tons of cardboard, conserving 500,000 barrels of oil, and avoiding 442 tons of CO2 emissions. A sustainability survey conducted by Thepacker.com, the fresh fruit and vegetable industry's leading source for news, information and analysis, provides further evidence of the importance of sustainable products to consumers. More than half of consumers surveyed were more likely to buy products labeled as "climate-smart," 54% prefer recyclable packaging, and 25% indicated that they only buy from brands that can demonstrate how the brand addresses climate change. Attributes rated highly by consumers regarding the impact on sustainability of the food they bought were recyclable packaging, 57%, low carbon footprint, 50%, and urban and vertical farming, 41%. These results demonstrate why our ESG/sustainability approach has resonated extremely well with both retailers and consumers who care about the environmental impact of the food supply chain, which we expect will help Edible Garden expand our distribution channels and drive demand for our products. Our Zero-Waste Inspired approach is integral in everything we do. Innovative recyclable packaging minimizes the use of plastics and has successfully reduced waste and shrinkage at our supermarket customers by increasing the shelf life of our products, thereby reducing spoilage. For example, using our packaging technologies, cilantro maintains its quality for up to 11 days, or more than 50% longer than seven days with conventional packaging. In fact, this technology has led to a significant decline in product shrinkage among retailers. Our hydro basil, packaged in a recyclable and biodegradable pot, increasingly available in major supermarket chains in the northeast, is a perfect example of our approach and goal of reducing plastic consumption. We plan to expand this program across more of our SKUs and with more of our retail partners as we move forward."

08:42 EDT AGCO celebrates 175th anniversary of Massey Ferguson brand - AGCO Corporation proudly celebrates the 175th anniversary of its Massey Ferguson brand. As the first company to sell agricultural products on a global scale, Massey Ferguson has provided straightforward, dependable solutions for generations of farmers. The brand celebrates this milestone anniversary with a renewed dedication to farmer-focused innovation, embodied by the Massey Ferguson 8S Series tractor and the rest of the MF S Series lineup.

08:40 EDT T2 Biosystems implements expense reductions including workforce reduction - Implemented expense reductions on June 1, 2022, reducing the workforce by eliminating 34 existing and 20 planned positions, and decreasing operating expenses by approximately 20%.

08:38 EDT E-Home Household Service awarded household service contract - E-Home Household Service has been awarded a service contract from PICC Property and Casualty's Fujian company to provide property and household appliance cleaning and maintenance services for PICC Fujian's clients. E-Home will be the designated household service provider for PICC Fujian's insurance clients who purchase insurance products from PICC Fujian and are offered additional housekeeping services as part of an incentive rebate program. The partnership with PICC would bring in about RMB2M-RMB3M service revenue annually. Putian YouYou Cleaning, a subsidiary of the company, has been awarded RMB1.4M new property cleaning contract.

08:36 EDT Ace Global Business announces additional contribution to trust account - Ace Global Business Acquisition Limited, a special purpose acquisition company, announced that Ace Global Investment Limited, the Company's initial public offering sponsor, has deposited into the Company's trust account an aggregate of $455,400 in order to extend the period of time the Company has to complete a business combination for an additional three months period, from July 9, 2022 to October 8, 2022. The Company issued a promissory note to the Sponsor with a principal amount equal to the amount deposited. The purpose of the extension is to provide time for the Company to complete a business combination.

08:34 EDT SciSparc authorizes share buyback program for up to $1M - SciSparc's board of directors authorized the company to implement a $1M buyback program for the company's ordinary shares. The company expects to formally approve the buyback in conjunction with the approval of its financial statements for the 6 months ended June 30, 2022, together with a financial advisor's opinion to be obtained. The company is required to file a motion seeking a court approval in Israel for the buyback program, and the effectiveness of the buyback plan, if formally approved, will be contingent upon such court's approval.

08:33 EDT Coherus, Junshi announces FDA acceptance of resubmission of Toripalimab BLA - Coherus BioSciences and Shanghai Junshi Biosciences announced that the United States Food and Drug Administration has accepted for review the Biologics License Application resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinomaand for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has set a Prescription Drug User Fee Act action date for December 23, 2022. The Agency earlier communicated that the review timeline for the BLA resubmission would be six months, as onsite inspections in China would be required. Travel restrictions related to the COVID-19 pandemic previously hindered the FDA's ability to complete required inspections. Coherus plans to launch toripalimab in the United States in the first quarter of 2023, if approved.

08:33 EDT Allison Transmission selected to propel new M88A3 HERCULES prototype vehicles - Allison Transmission will provide the X1100TM-5B propulsion solution for the U.S. Army's new M88A3 HERCULES prototype vehicle. This initiative is consistent with the Army's continued investments in combat readiness and fleet modernization and represents more than $37 million in engineering design, development, fabrication, testing, and demonstration funds for Allison's X1100TM-5B for the M88A3 HERCULES prototype vehicles through 2023. A decision by the Army to transition to production is expected in early 2024. Currently, there are more than 900 M88 vehicles in the U.S. Army. The M1A2 Abrams Main Battle Tank requires two M88A2 heavy tracked recovery vehicles to tow the vehicle. The U.S. Army modernization program's goal is to regain single vehicle recovery of the Army's heaviest tracked vehicle providing more efficient use of resources.

08:32 EDT Splash Beverage signs new distribution deal in New Mexico with Brewer Oil Co. - Splash Beverage will now be selling all four SKUs of TapouT Performance Drinks into Convenience Store Chain, Brewer Oil Company in New Mexico. Brewer Oil Company, headquartered in Albuquerque, New Mexico was founded in 1958 with an initial service station in Artesia. Brewer Oil serves wholesale and retail customers with automotive and retail convenience stores throughout New Mexico.

08:31 EDT Rail Vision launches long-term pilot program with Rio Tinto - Rail Vision (RVSN) announced that it has launched a long-term pilot program with Rio Tinto Iron Ore (RIO) for the AutoHaul project, the world's first automated, long distance, heavy haul rail network. As part of the Company's contract with Hitachi Rails STS, the lead project technology partner and integrator, the Rail Vision Main Line System will be tested in Pilbara Western Australia for a duration of three months under the long-term pilot program with an option to extend for an additional six months in different use-cases. As part of the AutoHaul project, 2.4-kilometer-long trains, monitored remotely from an operations center in Perth, travel across a vast network of 1,700 kilometers of track, delivering iron ore from 16 mines to ports in Dampier and Cape Lambert. These trains have now safely travelled more than 4.5 million kilometers autonomously since they were first deployed in 2018. Under the AutoHaul program, Rio Tinto is seeking to add a forward-looking capability to its autonomous trains to detect obstacles on and along the tracks. During the test phase of the Rail Vision Main Line system pilot, Rio Tinto and Hitachi will test different types of obstacles the system can detect and at various ranges.

08:29 EDT Hivello partners with DLTx to expand IoT hotspot network - Blockmate Ventures announces that its subsidiary Hivello has entered into a partnership with Web3 infrastructure company DLTx to expand the Hivello network of Internet of Things hotspots. By partnering with DLTx, Hivello will secure access to DLTx's suppliers, financiers, and management expertise which have been at the forefront of developing and launching 10 of the most important protocols in the blockchain space, including Ethereum. Hivello will issue equity to DLTx which will receive a 40% stake in Hivello while Blockmate retains the remaining 60%. Both parties will be subject to dilution from new capital on a pro rata basis from Hivello's current USD $5 million capital raise through private equity channels. DLTx will also be invited to appoint a representative to Hivello's Board of Directors.

08:26 EDT Applied Molecular Transport announces Phase 2 results from MARKET trial - Applied Molecular Transport announced top-line Phase 2 results from the MARKET combination trial for AMT-101 in biologic-naive patients with moderate-to-severe UC. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT's proprietary carrier molecule. In the MARKET trial, patients received either once-daily oral AMT-101 3mg in combination with adalimumab, or adalimumab alone. The objectives of the MARKET trial were to assess the safety and efficacy of AMT-101 in combination with anti-TNFalpha therapy in patients with moderate-to-severe UC. The key efficacy endpoint of clinical remission was measured at 8 weeks. The clinical remission rate in the adalimumab alone arm was higher than historical anti-TNFalpha monotherapy benchmarks, and the data from the MARKET trial did not demonstrate added clinical benefit in the combination arm compared to the adalimumab alone arm at week 8. Of the 49 evaluable patients, 31.8% of patients treated in the combination arm achieved clinical remission versus 33.3% in patients receiving adalimumab alone at week 8. Clinical remission is defined as Mayo endoscopic subscore of 0 or 1, rectal bleeding subscore of 0 and stool frequency subscore of 0 or 1. AMT-101 appeared safe and well-tolerated. Treatment emergent adverse events were mostly mild to moderate, with one serious adverse event observed, worsening of UC, which was determined to be unrelated to study treatment. Overall patient demographics were balanced between the two arms with the exception of patients in the combination arm having much shorter duration of UC history versus patients in adalimumab alone arm. Based on this observation, we conducted a post hoc sub-group analysis to explore the potential effect of duration of UC history on clinical remission. Sub-group analysis revealed that patients with a shorter duration of UC had clinical remission rates of 43.8% in the combination arm versus 15.4% in the adalimumab alone arm. In patients with longer duration UC, clinical remission rates were 0.0% in the combination arm versus 50.0% in patients receiving adalimumab alone. These data suggest that combination treatment with AMT-101 earlier in the course of UC may be more beneficial than anti-TNFalpha alone within 5 years of diagnosis. Further evaluation and analyses are ongoing. The Company plans to present full trial results at an upcoming medical conference. AMT anticipates a number of milestones for its AMT-101 development program in IBD. For chronic pouchitis, FDA has granted an end of Phase 2 meeting for AMT-101 to discuss Phase 3 development. The company also anticipates top-line results from its ongoing AMT-101 Phase 2 LOMBARD monotherapy trial for UC in the second half of 2022.

08:25 EDT Enphase Energy expands IQ8 Microinverter deployments in Massachusetts - Enphase Energy announced that installers of Enphase products in Massachusetts have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters following the product's launch in North America late last year. Residential solar deployments in Massachusetts are predicted to reach just over 94 MW in 2022, representing over 600% growth over the last decade. Enphase's IQ8-based systems can provide Sunlight Backup during an outage, even without a battery.

08:23 EDT Vuzix reports follow-on smart glasses order valued at over $350,000 - Yesterday, Vuzix announced that they have received and begun delivering a follow-on smart glasses order valued at over $350,000 for "a large US multinational retailer" to support their warehousing and logistics needs. "Sizable further follow-on orders are anticipated as rollouts successfully continue, according to the customer. This customer represents the Company's latest of four Fortune 100 retailers that are using Vuzix smart glasses," Vuzix stated in a press release dated July 5.

08:23 EDT Sarepta's Duchenne muscular dystrophy candidate shows efficacy in studies - Sarepta (SRPT) and its partner Roche (RHHBY) presented new results and analyses at the International Congress on Neuromuscular Diseases, which demonstrate that SRP-9001 shows consistent, statistically significant functional benefits in individuals with Duchenne versus a propensity-weighted external control that continue to positively diverge from natural history disease course. SRP-9001-treated participants improved 4 points from their pre-therapy baselines, and 3.8 points and 3.2 points at 52 weeks on the North Star Ambulatory Assessment vs. external control group. Results from ENDEAVOR support the company's ongoing Phase 3 study. In a 4-patient study, at 4 years, patients - currently on average over 9 years old and in the predicted steep decline phase of disease - did not decline but showed a 7-point increase above their pre-treatment baselines on NSAA, and improvement versus external control. In a 52-patient integrated analysis at target dose, at one year, SRP-9001 treated patients improved 3.1 points and 2.4 points on NSAA versus external control. Safety and tolerability profile for SRP-9001 remains consistent across treated patients. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche.

08:22 EDT DoorDash, Uber slide after Amazon strikes deal with Grubhub - Shares of DoorDash (DASH) and Uber Eats parent Uber (UBER) are lower in pre-market trading after Just Eat Takeaway.com N.V. (TKAYY) announced a commercial agreement with Amazon.com Services (AMZN) in the United States. Under the commercial agreement, a subsidiary of Amazon will receive warrants over 2% of Grubhub's fully-diluted common equity. Amazon will also receive warrants over up to a further 13% of Grubhub's fully-diluted common equity, the company reported. "Starting today, Amazon Prime members in the United States can sign up for a free, one-year Grubhub+ membership and access unlimited $0 delivery fees from hundreds of thousands of restaurants on Grubhub throughout the year," the announcement added. In pre-market trading, Uber shares have slid 76c, or 3%, to $21.76, while DoorDash shares are down $5.05, or 7%, to $69.85.

08:19 EDT Immutep granted Japanese patent for IMP761 - Immutep is pleased to announce the grant of a new patent entitled "Anti-LAG-3 Antibodies" by the Japanese Patent Office. This new Japanese patent follows the grant of the equivalent European patent announced in October 2020. The claims of the patent are directed to Immutep's pre-clinical product candidate IMP761, pharmaceutical compositions comprising IMP761, and the use of the compositions in the treatment of T-cell mediated inflammatory and autoimmune diseases. The expiry date of the patent is 1 September 2036.

08:18 EDT Poet announces sampling of 200G FR4 Transmit, Receive Optical Engines - POET Technologies announced sampling of its 200G FR4 Transmit and Receive Optical Engines. The Optical Engines are based on the POET Optical Interposer, a unique hybrid integration photonics packaging platform. The Company has shipped samples to multiple lead customers through Super Photonics, its joint venture with Sanan IC, and expects the 200G FR4 TX and RX Optical Engines to be in production at Super Photonics by the end of 2022.

08:17 EDT Cerberus Cyber completes acquisition of CyberViking - Cerberus Cyber has completed the acquisition of CyberViking, a cybersecurity company based in Georgia and Oregon. Upon the closing of the transaction, CyberViking became a wholly owned subsidiary of Cerberus Sentinel. CyberViking specializes in application security services, incident response and threat hunting, and the creation and management of security operations centers.

08:16 EDT NextCure reports publication supporting development of cancer candidate NC318 - NextCure announced the publication of a paper in Laboratory Investigation that outlines data from a study utilizing a newly developed antibody to Siglec-15, or S15, and an immunhistochemical assay to investigate S15 expression in solid tumors. The company believes that these data support its development of therapeutic candidates like NC318, which target S15 to restore immune cell function and anti-tumor responses in patients with cancer. Expression of S15 on NSCLC supports clinical trials evaluating therapeutics targeting S15 and highlights the importance of patient selection in the ongoing NC318 clinical trial. NextCure believes NC318 has the potential to treat multiple cancer types.

08:15 EDT Coherus, Junshi announces FDA acceptance of resubmission of Toripalimab BLA - Shanghai Junshi Biosciences and Coherus BioSciences announced that the United States Food and Drug Administration has accepted for review the Biologics License Application resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has set a Prescription Drug User Fee Act action date for December 23, 2022. The Agency earlier communicated that the review timeline for the BLA resubmission would be six months, as onsite inspections in China would be required. Travel restrictions related to the COVID-19 pandemic previously hindered the FDA's ability to complete required inspections. Coherus plans to launch toripalimab in the United States in the first quarter of 2023, if approved.

08:13 EDT Spire Marketing to provide RSG through agreement with Ascent Resources - Spire Marketing has completed a multi-year agreement to purchase responsibly sourced gas, RSG, from Ascent Resources. The agreement with Ascent represents the first RSG transaction for Spire Marketing. "Increasingly over the past few months, we have received numerous requests from our clients regarding access to RSG. Our agreement with Ascent now provides us with the ability to bring this value to our clients throughout North America," said Patrick Strange, Spire Marketing President. "Meeting the current and future needs of our clients, both from a reliability and sustainability standpoint, is core for Spire Marketing and our parent Spire. We are thankful to Ascent Resources for their continued leadership in the natural gas market and for their support in helping us add RSG to our portfolio."

08:12 EDT Catalyst Biosciences says court denies JDS1's motion for expedited proceedings - Catalyst Biosciences announced that the Delaware Court of Chancery has denied the motion for expedited proceedings in the action brought by the plaintiff, JDS1. In making its determination, the Court ruled that it "[did] not view [JDS1's disclosure] claim as colorable" and indicated that that those claims "have effectively been mooted." "We are pleased that the Delaware Court of Chancery has rejected JDS1's request for an expedited proceeding with respect to our disclosures relating to the recently completed sale of a portion of our product portfolio for up to $60 million in cash," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "As we have described in detail in our public filings, the sale was the culmination of a thorough, competitive process that we believe maximizes value for our stockholders. As we previously indicated, the Board and the Company are actively controlling the Company's expenses while seeking to monetize its remaining assets. And while we welcome the opportunity to further demonstrate the propriety of our actions in court, we (and all the many stockholders with whom we have spoken) would prefer for JDS1 to drop its lawsuit and proxy contest, both of which are depleting the resources of the Company. The Board remains committed to distributing its cash, net of liabilities and obligations, expeditiously to stockholders once the potential liabilities and expenses associated with the stockholder litigation and the proxy contest are known."

08:10 EDT Yoshitsu partners with iEnt for duty-free E-market for foreigners in Japan - Yoshitsu has signed a service agreement with iEnt, a digital transformation service company that provides Online-Merge-Offline solutions and operates a duty-free shopping website, TaxFreeOnline, to enter the domestic duty-free E-commerce market for foreign visitors. In partnering with iEnt, the company plans to list its Japanese beauty, health and other products on TFO and leverage iEnt's network and expertise in DX service and OMO solutions to provide more foreign visitors with access to the company's duty-free Japanese products.

08:10 EDT Global Crossing Airlines announces ACAP lease for aircraft maintenance facility - Global Crossing Airlines Group announces that American Corporate Airport Partners has inked a long-term ground lease with Broward County to construct a widebody-capable, aircraft maintenance facility for GlobalX at Broward County's Fort Lauderdale-Hollywood International Airport. The estimated $25 million, 10-acre maintenance complex at a mid-field site on SW 41st Ct. is expected to consist of a 54,000 sf hangar; an aircraft ramp for staging and maneuvering; technical shops and office space; environmentally friendly building systems; and automobile parking, all in a build-to-suit layout exclusively for GlobalX, a passenger and cargo charter airline. The airline maintenance complex is expected to be operational in 4Q 2023 and generate 100 permanent, full-time jobs.

08:09 EDT Corporate Spending Innovations enters definitive agreement with The Bancorp - Corporate Spending Innovations, a division of Edenred (EDNMY), has entered into a definitive Banking Identification Number, BIN, sponsorship agreement with The Bancorp Bank, a wholly-owned subsidiary of The Bancorp (TBBK). This sponsorship from The Bancorp, through its Fintech Solutions business, will facilitate the next level of CSI's integrated payments processing and dual card issuing capabilities, accelerating growth of CSI's leading integrated B2B payment programs and expanding the CSI payment network. As an extension to its existing relationship with Edenred, this partnership combines more than 15 years of The Bancorp Fintech Solutions' BIN sponsorship experience with CSI's market-leading accounts payable automation platform.

08:08 EDT Femasys appoints Charles Larsen as chairperson of the board - Femasys announced that Charles Larsen, a current member of Femasys' Board of Directors, has been appointed to the role of non-executive Chair, replacing founder, president and CEO, Kathy Lee-Sepsick. Mr. Larsen has served as a member of Femasys' board of directors since October 2015.

08:06 EDT BlackBerry's QNX technology selected by Volkswagen's software company - BlackBerry (BB) announced that CARIAD, the Volkswagen Group's (VWAGY) software company has selected BlackBerry QNX technology as one component of its software platform VW.OS. Announced as part of Volkswagen Group's NEW AUTO strategy, CARIAD is developing a unified software platform that consists of VW.OS, the Volkswagen Cloud VW.AC and a scalable, unified end-to-end electronic architecture. The platform will be available for Volkswagen Group brands from the middle of the decade. BlackBerry will license its BlackBerry QNX technology to CARIAD, including its QNX OS for Safety 2.2. It will be integrated in CARIAD's software platform VW.OS, specifically in the stack for advanced driver assistance systems and automated driving functions.

08:06 EDT Immunome says IMM-BCP-01 retained activity against Omicron subvariants - Immunome announced that their cocktail, IMM-BCP-01, retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing. IMM-BCP-01 is currently in Phase 1b clinical testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5 and BA.2. IMM-BCP-01 is a three-antibody cocktail with each antibody having a different mechanism of action. IMM20190 binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop preventing binding to ACE2. IMM20184 and IMM20253 neutralized live BA.2 Omicron variant in in vitro testing as well as pseudoviruses corresponding to the BA.2.12.1 and BA.4/.5 subvariants. In particular, IMM20253 neutralized the virus through an ACE2-independent mechanism that differs from the neutralization mechanisms used by current or past antibodies approved for clinical use. Data recently published in Science Immunology provides a mechanistic basis for how IMM20253 binding, which is conserved across all variants to date including Omicron and its sub-lineages, neutralized SARS-CoV-2. "We are pleased that IMM-BCP-01 retains effectiveness against the currently dominant BA.4/.5 and BA.2.12.1 subvariants," stated Purnanand Sarma, PhD, President & CEO of Immunome. "Further, as several existing antibody treatments lose their potency against the Omicron subvariants, IMM-BCP-01 continues to retain activity against these variants in preclinical testing and we believe our cocktail has potential to play a significant role in managing the pandemic. We also look forward to announcing topline data from our Phase 1b clinical study in the second half of 2022."

08:04 EDT Caladrius and Cend announce publication of pancreatic cancer trial data - Caladrius and Cend Therapeutics, a privately-held, clinical-stage drug discovery and development company developing a novel approach to enable more effective treatments for solid tumor cancers, pursuant to a collaboration agreement entered into by each company in connection with their recently announced and pending merger to form Lisata Therapeutics, announced that The Lancet Gastroenterology and Hepatology has published data from the Phase 1b study of CEND-1, Cend's lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma - mPDAC -. The objectives of the study were to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with mPDAC. New results suggest a potential for marked and durable improvement in treatment effectiveness in combination with standard-of-care drugs for mPDAC. CEND-1 was well tolerated; no dose-limiting toxicities were identified; safety of the combination was consistent with SoC alone. Median Progression-Free Survival was 9.7 months. Median Overall Survival was 13.2 months, Overall Response Rate was 59%, Disease Control Rate at 16 weeks 90%, CA19-9 circulating tumor biomarker reductions of 50% or greater in 91% of patients.

08:02 EDT Enovis completes acquisition of Insight Medical Systems - Enovis announced that it has acquired Insight Medical Systems, a technology company dedicated to reimagining orthopedic surgical guidance. Insight's flagship solution, ARVIS, is the only FDA-cleared augmented reality solution precisely engineered for the specific needs of hip and knee replacement surgery. Financial terms of the transaction were not disclosed. Since Enovis' initial investment in Insight Medical Systems in 2020 and a follow-on funding round in 2021, the company received 510(k) FDA clearance for the ARVIS Augmented Reality System and successfully completed over 200 cases in the U.S. ARVIS will be commercially available in Q3 of 2022 and the Insight team will become part of the Enovis Surgical organization with the goal of driving further growth and expansion of the company's orthopedic enabling technologies platform.

07:46 EDT American Battery appoints Thomas Nagel as senior analytical chemist - American Battery Technology Company (ABML) welcomes Thomas Nagel as the newest Senior Analytical Chemist. Prior to joining ABTC, Nagel worked for five years at Tesla (TSLA) within the Gigalab quality laboratory at its Reno Gigafactory, holding various positions including Production Associate, Maintenance Technician, Analytical Chemistry Technician, and Associated Analytical Chemistry Scientist. As a Senior Analytical Chemist at ABTC, Nagel will be part of the company's growing technology team currently housed at the University of Nevada, Reno's Nevada Center for Applied Research. He will play a significant role in the company's abilities to advance and implement the rigorous methods of material characterization that are needed to certify in-house manufactured battery grade materials, from both the recycling of spent batteries and primary materials, to meet all customer specifications.

07:44 EDT Marathon Gold announces updated MRE for Valentine Gold Project - Marathon Gold is pleased to report an update to the Mineral Resource Estimates for the Valentine Gold Project in central Newfoundland . The new estimates incorporate approximately 100,000 metres of drilling completed at the Berry Deposit and the results of a 2021 Reverse Circulation drill program completed at the Marathon and Leprechaun Deposits. Aggregate MRE highlights of the Marathon, Leprechaun, Berry, Sprite, and Victory Deposits are as follows: Total Measured and Indicated Mineral Resources of 4.0 Moz Au, increases of +26% in ounces, +14% in tonnes and +10% in grade compared to the previous estimate. "High Grade" open-pit Measured and Indicated Mineral Resources of 3.4 Moz Au, increases of +28% in ounces, +22% in tonnes and +5% in grade compared to the previous estimate. Additional Inferred Mineral Resources of 1.1 Moz Au. Within the aggregate MRE estimates, the newly defined Berry Deposit is confirmed as a major new contributor of Mineral Resources at the Project: Berry Measured and Indicated Mineral Resources of 1.1 Moz Au. Additional Berry Inferred Mineral Resources of 0.25 Moz Au. Mineral resources which are not mineral reserves do not have demonstrated economic viability. Matt Manson, President and CEO, commented: "This updated Mineral Resource Estimate is the largest in quantity, the highest in grade, and the best in quality that has ever been produced for the Valentine Gold Project. It incorporates two years of exploration drilling at the Berry Deposit, which is now confirmed to be comparable in scale and gold content to the nearby Leprechaun Deposit. As a reminder, Berry is located immediately adjacent to the proposed site of the Project's gold mill. The new estimate also incorporates, and is successfully validated by, the results of our 2021 RC drill program, where we set out to test our assumptions about the scale and continuity of the gold mineralization at Valentine. As well as the new drilling datasets, the 2022 MRE benefits from new geological models, updated gold price and exchange rate assumptions, updated estimates for mining and processing costs, and new Whittle pit shells. The assessment work now completed on the Project's Mineral Resources is comprehensive, and has been conducted with a view to achieving the maximum possible confidence in the investment merits of the Project prior to breaking ground. As we have done this, the Project has continued to grow through our ongoing exploration efforts. In parallel with our permitting and engineering work, therefore, a study is underway to consider the opportunities offered by the 2022 MRE on the Project's Mineral Reserves, production profile and mine life. The results of this study will be incorporated into a new National Instrument 43-101 Technical Report, which will constitute an Updated Feasibility Study for the Valentine Gold Project. This work is on schedule for completion in the fourth quarter of this year."

07:41 EDT Veru's sabizabulin shows reduction of COVID-19 deaths in published trial - Veru announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome - ARDS - and death in The New England Journal of Medicine Evidence. The Phase 3 COVID-19 clinical trial is a study evaluating dosing of sabizabulin 9 mg versus placebo in approximately 210 hospitalized moderate to severe COVID-19 patients who were at high risk for ARDS and death. For the primary efficacy endpoint, death at or before day 60, sabizabulin treatment resulted in a clinically and statistically meaningful 55.2% relative reduction in deaths in the intent to treat population. The placebo group had a 45.1% mortality rate compared to the sabizabulin-treated group which had a 20.2% mortality rate. The key secondary endpoints included effects of sabizabulin treatment on mortality through Day 29, with a placebo mortality rate of 35.3% compared to sabizabulin treatment mortality rate of 17%, sabizabulin treatment resulted in an absolute reduction of 18.3 percentage points and a relative reduction in deaths of 51.8%. The company submitted a request for an EUA application on June 7. The company has scaled up manufacturing and expects to be able to produce sufficient commercial drug supply to address anticipated drug needs following potential FDA authorization in the U.S. and subsequent authorizations in other countries and regions. The company is having discussions with government agencies to discuss purchases and reimbursement for sabizabulin in the U.S. and other countries around the world.

07:40 EDT Air Products, VPI sign joint development agreement for hydrogen production - Air Products announces the signing of a joint development agreement to drive forward the "Humber Hydrogen Hub" or "H3", which seeks to develop a flagship 800MW low-carbon hydrogen production facility in Immingham, UK. The majority of hydrogen produced would be used to decarbonize VPI Immingham's existing power production. The agreement was signed by Air Products Chief Operating Officer Dr. Samir Serhan and VPI Chairman Russell Hardy. H3 would produce low-carbon hydrogen at large scale, combining hydrogen production, carbon capture technology and offshore CO2 storage currently under development for the Humber region. The H3 project looks to capture up to two million tonnes of CO2 per annum and contribute to achieving Net Zero in the wider Humber industrial region by 2040. The H3 project has submitted an application for "Strand 1" funding as part of the Net Zero Hydrogen Fund. Administered by UK Research and Innovation, the fund has the objective of enhancing hydrogen production at scale. It will contribute towards the UK Government's ambition of realizing 10GW of low-carbon hydrogen production by 2030. As both companies move towards an investment decision, this marks a significant step that could bring hundreds of new jobs to the region during construction and operation. Air Products' Chief Operating Officer Dr. Samir Serhan said: "We are excited to be working with VPI, a strong proponent for decarbonization in the Humber region. Having a partner who is committed to decarbonizing their existing power production operations through the use of low-carbon hydrogen provides the secure hydrogen offtake that makes this an excellent opportunity for us to support them and the UK Government's broader sustainability targets."

07:38 EDT Vera Therapeutics completes patient enrollment in Phase 2b ORIGIN trial - Vera Therapeutics announced completion of patient enrollment in the Phase 2b ORIGIN clinical trial of atacicept, the Company's potential disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator and a proliferation-inducing ligand. ORIGIN is a multinational dose-ranging study evaluating the efficacy and safety of atacicept in patients with IgA nephropathy who continue to have persistent proteinuria and remain at high risk of disease progression despite being on a stable prescribed regimen of renin-angiotensin-aldosterone system inhibition with an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker.

07:37 EDT Harpoon Therapeutics appoints Wendy Chang as SVP, human resources - Harpoon Therapeutics (HARP) announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine. Chang comes to Harpoon from IDbyDNA where she served as Vice President, Head of People & Culture. Prior to joining Harpoon, Dr. Anand served as Vice President, Head of Nonclinical Development/Clinical Pharmacology at Molecular Templates (MTEM).

07:35 EDT InflaRx's vilobelimab for ulcerative PG granted Fast Track Designation by FDA - InflaRx announced that the FDA granted a Fast Track designation to the development of its first-in-class anti-C5a monoclonal antibody vilobelimab for the treatment of ulcerative pyoderma gangrenosum, or PG. The company had submitted a request for Fast Track designation to the FDA on the positive outcome data in PG from its Phase IIa open-label dose-escalation study. In the multi-center, proof-of-concept Phase IIa study a total of 19 patients were enrolled. 6 out of 7 patients in the high dose cohort demonstrated complete target ulcer closure and treatment response correlated with suppression of C5a levels in patients' plasma over time. Vilobelimab was granted orphan drug designation for the treatment of PG by both the FDA in the US and the EMA in Europe and that the company had held a productive End-of-Phase II meeting with the Division of Dermatology with the FDA related to its Phase III development plans in PG.

07:33 EDT Cambium Networks fixed wireless broadband technology selected by US Army - Cambium Networks announced that they have delivered the initial order of Microwave Line-of-Sight radios to Advanced Technology Systems Company, ATSC, as a part of the the SSS program. ATSC is the prime contractor for the $191M indefinite delivery, indefinite quantity, IDIQ, contract for the U.S. Army's SSS program of record and a leader in force protection systems and border and maritime surveillance systems. The single award IDIQ contract with ATSC has an estimated completion date in 2029

07:15 EDT Apollo Endosurgery appoints Sharon O'Keefe to board of directors - Apollo Endosurgery announced that Sharon O'Keefe has joined the company's Board of Directors, effective July 6, 2022. O'Keefe was President of the University of Chicago Medical Center from 2011 to 2020, overseeing a network of physicians and clinics with 10,000 employees and annual operating revenue in excess of $2 billion. Apollo also announced that Rick Anderson has retired from the Apollo Board of Directors, effective immediately. Mr. Anderson, Chairman of Revival Healthcare Capital, has served as a member of the Apollo Board of Directors since 2013.

07:13 EDT Texas court grants ParkerVision motion to add willfulness to Intel complaint - ParkerVision announced a number of recent rulings with respect to its patent infringement cases in the Western District of Texas and related PTAB proceedings. ParkerVision v. Intel: The Court granted ParkerVision's motion to file an amended complaint in its patent infringement action against Intel which will add a claim of willful infringement to the case. In the same order, the Court denied an Intel motion to strike ParkerVIsion's final infringement contentions. ParkerVision v. LG Electronics: The Court issued its claim construction order in which the majority of the terms were decided in ParkerVision's favor. Nearly all of the terms disputed by the parties were identical to those terms constructed by the Court in ParkerVision v. Intel and other cases, and the Court adopted its same constuctions. ParkerVision v. Hisense and ParkerVision v. TCL: The Court issued a scheduling order setting a trial commencement date of February 13, 2023. The Patent Trial and Appeal Board issued its final decision in Intel's IPR action against claims of the ParkerVision patent no. 8,190,108 determining that all of the challenged claims of the '108 Patent are unpatentable. The '108 Patent is one of the patents in ParkerVision's second infringement case against Intel in the Western District of Texas.

07:11 EDT Xos delivers 58 electric stepvans to Merchants Fleet in Q2 - Xos announced the delivery of 58 of its 100% battery-electric stepvans to three locations for Merchants Fleet, a fleet management company, during Q2. The three locations include San Diego, Calif., North Highlands, Calif., and Hooksett, N.H.

07:10 EDT Cardinal Health acquires the Bendcare CPO-GPO entity - Cardinal Health announced that it has acquired the Bendcare group purchasing organization, CPO-GPO, entity and made a minority investment in the Bendcare management services organization, MSO. Following the acquisition of the CPO-GPO, current Bendcare-affiliated CPO-GPO members will transition to Cardinal Health's Cornerstone Rheumatology GPO, and Cardinal Health will be the exclusive distributor for those practices. This acquisition demonstrates Cardinal Health's strategy of prioritizing investment in strategic growth areas and expands distribution opportunities and technology solution offerings for specialty practices. Financial terms of the transaction were not disclosed.

07:09 EDT Colliers International completes investment in Rockwood Capital real estate firm - Colliers has completed its investment in Rockwood Capital, a U.S. real estate investment management firm with more than $12B of assets under management and offices in Los Angeles, San Francisco, and New York City.

07:08 EDT BeiGene teams with InnoRNA to develop mRNA-based therapeutics - BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA to leverage its innovative technology platform for developing mRNA-based therapeutics. Under the terms of the agreement, InnoRNA will receive an upfront cash payment and will be eligible to receive additional payments based upon the achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties, for the mRNA-LNP research collaboration programs. BeiGene will hold exclusive global development and commercialization rights for the mRNA-LNP therapies jointly discovered by InnoRNA and BeiGene. InnoRNA will receive an additional upfront cash payment and is eligible for additional milestone payments for granting BeiGene non-exclusive license to its proprietary LNP Technology platform. We are very excited to partner with BeiGene to discover and develop innovative mRNA therapies as well as contribute our LNP technology to BeiGene's internal research," said Linxian Li, Ph.D., Founder and Chief Executive Officer of InnoRNA. "As evidenced by the success of multiple Covid-19 vaccines, mRNA and LNPs will likely play a major role in the future of drug development, potentially in broad fields beyond vaccines. Joining this collaboration with BeiGene represents a big step forward toward this vision for our company."

07:07 EDT LabCorp to begin testing for monkeypox - LabCorp announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention's, or CDC, orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox. This effort is part of the administration's commitment to quickly increase monkeypox testing access and capacity in every community during the ongoing outbreak.

07:06 EDT Alta Equipment Group to acquire privately held Yale Industrial Trucks, no terms - Alta Equipment Group announced that it has entered into a definitive agreement to acquire Yale Industrial Trucks, a privately held Yale lift truck dealer with five locations in southeastern Canada. The company provides sales, service, and rental of material handling equipment throughout its territory, which encompasses Canada's two largest population centers of Toronto and Montreal. .."This acquisition extends our operations into an international market for the first time and bridges our existing U.S. territories. It will benefit our Material Handling business as Quebec and Ontario represent approximately 80% of the market opportunity in Canada, and the greater Toronto area is one of the top five industrial distribution markets in North America. Culturally, they have a rich 50-year history of providing outstanding service to customers in the Canadian market which fits with our focus. We're pleased to welcome YIT to the Alta family." YIT generated approximately $46.6M in revenue and adjusted EBITDA of $9.4M in the trailing twelve months through May 2022. The implied enterprise value of the acquisition is estimated to be approximately $33.5M, subject to post-closing purchase price adjustments. The Company expects to close both the acquisition of YIT and the amendments to its credit agreements in the third quarter.

07:05 EDT Rogers, Shaw report no resolution in mediation with Commissioner of Competition - The companies said, "The early mediation between Rogers Communications (RCI), Shaw Communications (SJR), and the Commissioner of Competition on July 4 and July 5, 2022, did not result in a resolution of the Commissioner's objections to the proposed merger. The review process will continue as previously disclosed. Rogers and Shaw are not precluded from continuing discussions with the Commissioner at any time. Rogers and Shaw intend to continue to work constructively with the Commissioner to highlight the many benefits of the merger to all Canadians, including maintaining a strong and sustainable fourth wireless carrier across Canada through the proposed divestiture of Freedom Wireless to Quebecor Inc."

07:04 EDT Rogers, Shaw report no resolution in mediation with Commissioner of Competition - The companies said, "The early mediation between Rogers Communications (RCI), Shaw Communications (SJR), and the Commissioner of Competition on July 4 and July 5, 2022, did not result in a resolution of the Commissioner's objections to the proposed merger. The review process will continue as previously disclosed. Rogers and Shaw are not precluded from continuing discussions with the Commissioner at any time. Rogers and Shaw intend to continue to work constructively with the Commissioner to highlight the many benefits of the merger to all Canadians, including maintaining a strong and sustainable fourth wireless carrier across Canada through the proposed divestiture of Freedom Wireless to Quebecor Inc."

07:03 EDT Kirkland's partners with Ryder to launch in-home delivery service - Kirkland's (KIRK) has partnered with Ryder System (R) to launch an in-home delivery service that will provide last-mile delivery and light assembly to customers. The nationwide program first test launched in more than 25 major markets in June 2022 and is expected to be rolled out across the lower 48 states by the end of July. "Launching our new in-home delivery program through an industry-leading partner like Ryder is a pivotal milestone in the transformation of Kirkland's Home," said Steve "Woody" Woodward, president and CEO of Kirkland's Home. "As we continue to evolve our merchandise mix into high-quality designs with a value-centric mindset, it was necessary to upgrade our logistics capabilities and make it easier for customers to enjoy our products. Utilizing Ryder's proven platform, which manages in-home delivery for many of our peers in the home-furnishing space, gives us the utmost confidence that consumers will have a seamless and positive experience receiving furniture and bulky items directly to their homes. We believe that this program has the potential to expand our customer base and allows our offerings to be more competitive than ever before."

07:00 EDT Broadridge appoints Tyler Derr as CTO - Broadridge announced that Tyler Derr has been appointed CTO effective July 1. In this role, he will serve as the senior-most technology officer in Broadridge's delivery of SaaS and other service offerings to leading financial services clients. He will be responsible for overseeing Broadridge's global technology teams including enterprise-wide software engineering, product delivery, architecture, infrastructure, cybersecurity, and technology operations.

06:58 EDT Schweitzer-Mauduit, Neenah complete merger to become Mativ - Mativ Holdings ( MATV) announced the completion of the merger of equals between Schweitzer-Mauduit International (SWM" and Neenah (NP), two global manufacturers of specialty materials, effective July 6, 2022. Mativ has approximately $3B in sales, supporting customers in more than 100 countries, and manufacturing capabilities on four continents. Beginning Wednesday, July 6, 2022, the Company will commence trading on the New York Stock Exchange at the market open, under the new ticker symbol "MATV." Pursuant to the merger agreement, Neenah shareholders received 1.358 shares of SWM common stock for each share of Neenah common stock owned. SWM's shareholders will continue to hold their shares of SWM common stock. All SWM shares are now shares of Mativ common stock. Mativ will disclose financial results for two reporting segments: Advanced Technical Materials and Fiber-Based Solutions. The ATM segment is comprised of five non-reporting business units: Filtration, Protective Solutions, Release Liners, Healthcare, and Industrials. This segment generally represents the combination of SWM's legacy Advanced Materials and Structures and Neenah's Technical Products reporting segments. ATM will deliver solutions that filter and purify air and liquids, support adhesive and protective applications, advance healing and wellness, and solve some of material science's most demanding performance needs. The FBS segment is comprised of two non-reporting business units: Engineered Papers and Packaging and Specialty Paper - and represents SWM and Neenah's respective legacy paper segments. FBS will leverage the combined company's extensive natural fiber capabilities to provide specialty solutions for various end-uses, including sustainable packaging, imaging and communications, home and office, and consumer goods, among other applications. For the second quarter of 2022, Mativ will report financial results for legacy SWM and select financial and business highlights from Neenah. A call to discuss results, business performance, and future outlook, will be scheduled for August 10, 2022. Beginning in the third quarter of 2022, Mativ's financials will be reported on a consolidated basis consistent with the timing effectiveness of the merger.

06:53 EDT Piedmont Lithium added to Russell 2000 Index - Piedmont Lithium was added as a member of the U.S. Russell 2000 Index and the Russell Microcap Index as part of the 2022 Russell indexes reconstitution.

06:49 EDT Adva Optical announces approval of public exchange offer of Acorn HoldCo - The German Federal Ministry for Economics and Climate Protection has granted the foreign direct investment approval that was required for closing the public exchange offer made by ADTRAN's subsidiary, Acorn HoldCo. With the foreign direct investment approval by the BMWK, all offer conditions for Acorn HoldCo's public exchange offer published on 12 November 2021 are fulfilled. The settlement of the exchange offer is expected by 15 July 2022, but at the latest on 18 July 2022. Acorn HoldCo's shares will be admitted to trading on NASDAQ and the Frankfurt Stock Exchange.

06:47 EDT Stantec selected as Program Managment Consultant for IIWWTP projects - Stantec has been selected as the Program Management Consultant for the Iona Island Wastewater Treatment Plant Projects in Vancouver, British Columbia. The C$9.9 billion multi-year program includes construction of a new tertiary treatment facility and a range of ecological restoration and off-site works projects that will improve the connection between infrastructure, the community, and the environment. As PMC, Stantec will collaborate with Metro Vancouver to provide a variety of management and technical functions. These include program mobilization, program management, cost and schedule control, design management and technical integration, construction administration, permitting and approvals support, communications and engagement support, and commissioning and operations integration support. Completion of the IIWWTP Projects is currently scheduled for 2038 with tertiary treatment commissioning in 2035.

06:38 EDT MarketAxess reports June total trading ADV of $33.4B, up 29% - MarketAxess Holdings announced trading volume for June 2022 and trading volume and preliminary variable transaction fees per million for the quarter ended June 30, 2022. Select June 2022 highlights: U.S. high-grade average daily volume of $5.8 billion, up 9%; estimated market share of 22.7%, up from 21.9%. Record U.S. high-yield ADV of $2.0 billion, up 44%; record estimated market share of 19.0%, up from 13.7%. Emerging markets ADV of $2.9 billion, up 6%; estimated market ADV down 6%. Excluding the impact of currency fluctuations, emerging markets ADV in June 2022 was up approximately 9%. Record Eurobond ADV of $1.6 billion, up 17%; record estimated market share of 17.2%, up from 11.1%. Excluding the impact of currency fluctuations, Eurobonds ADV in June 2022 was up approximately 33%. Record composite corporate bond estimated market share of 21.2%, up from 17.9%. Municipal bond ADV of $379 million with strong market share gains. Total credit ADV of $12.7 billion up 16%; 92% of credit volume on the platform was executed by institutional clients. 36% of total credit trading volume was executed via Open Trading. Estimated total cost savings from Open Trading were approximately $94 million in June and average cost savings per million from Open Trading in June was $1,121. $20.2 billion in U.S. Treasury ADV, up 39% with market volumes down 9%.

06:33 EDT Healthcare Realty Trust's transaction with HTA recommended by Glass Lewis - Healthcare Realty Trust announced that independent proxy advisory firm Glass Lewis recommends that Healthcare Realty shareholders vote "for" the transaction with Healthcare Trust of America, or HTA. This recommendation joins ISS' support as well as the Board's unanimous recommendation that shareholders vote "for" the transaction at its upcoming special meeting of Healthcare Realty shareholders on July 15.

06:32 EDT BitNile self-mines 46.4 bitcoin in June - BitNile Holdings published an unaudited update on Bitcoin production and miner deliveries. The number of miners and production capacity metrics set forth within this press release represent the S19j Pro Antminers at the Michigan Data Center. BitNile's Bitcoin mining production is currently operating at an estimated annualized run rate of 698 Bitcoin based on current market conditions, including a mining difficulty of 29.57 trillion. BitNile has 9,645 S19j Pro Antminers in its possession and once installed will generate a combined processing power of approximately 965.5 petahashes per second, the computational power that is being used to mine Bitcoin. During the month of June 2022, BitNile self-mined 46.4 Bitcoin. To date, BitNile has mined a total of 256.5 Bitcoin. As of June 30, 2022, BitNile held 140.8 Bitcoin and currently has no plans to sell. As previously disclosed, BitNile has entered into purchase agreements with Bitmain Technologies for a total of 20,600 Bitcoin miners, including 4,600 environmentally friendly S19 XP Antminers that feature a processing power of 140 terahashes per second and 16,000 S19j Pro Antminers that feature a processing power of 100 TH/s. BitNile began receiving 300 S19j Pro Antminers per month in November 2021 in accordance with the purchase agreements it has executed with Bitmain. Beginning in March 2022, this schedule increased to 2,300 miners per month. Once all 20,600 miners are fully deployed and operational, BitNile is expected to achieve mining production capacity of approximately 2.24 exahashes per second.

06:29 EDT N-able acquire Spinpanel, terms not disclosed - N-able, announced it has acquired Spinpanel. A multi-tenant Microsoft 365 management and automation platform built for Microsoft Cloud Solution Provider to automate the provisioning, security, and management of all Microsoft tenants, users, and licenses in a single consolidated hub, Spinpanel helps direct and indirect CSPs reduce complexity, bring efficiency, and profitably scale their Microsoft business. Founded in 2015 as a spin-off of direct CSP, Spinpanel is used by a growing number of Microsoft partners and IT organizations across the globe. A significant majority of N-able partners manage and/or resell Microsoft Cloud services for their small and medium enterprise customers. The acquisition will help N-able partners alleviate two macro challenges-labor scarcity and moving to the cloud-to help partners tame the Microsoft Cloud and drive more value for their customers. In turn, Spinpanel customers will have more direct access to the N-able portfolio of powerful, scalable solutions and free educational and marketing resources to help them excel at every stage of growth. The addition of the Spinpanel technology into the N-able product portfolio is anticipated to occur during the third quarter. Further details regarding the transaction were not disclosed.

06:17 EDT Krispy Kreme to give away 8,500 years of free Original Glazed doughnuts - Krispy Kreme will celebrate 85 years of serving its Original Glazed Doughnuts with a week of deals for fans, including giving away 8,500 years of FREE Original Glazed dozens. Beginning Monday, July 11 through Thursday, July 14, every participating Krispy Kreme shop in the U.S. will randomly select multiple guests each day to receive a Krispy Kreme 85th birthday card worth free Original Glazed doughnuts for a year - one dozen per month through June 2023. A total of 8,500 years of free doughnuts will be given away. On Friday, July 15, Krispy Kreme fans can get an Original Glazed dozen for just 85 cents with the purchase of any regular price dozen.

06:13 EDT Patterson-UTI reports an average of 124 drilling rigs in June - Patterson-UTI reported that for the month of June 2022, the Company had an average of 124 drilling rigs operating in the United States. For the three months ended June 30, 2022, the Company had an average of 121 drilling rigs operating in the United States.

06:08 EDT Ensign Group acquires real estate assets in California - The Ensign Group announced that Standard Bearer Healthcare REIT, Inc., a subsidiary of Ensign, acquired the real estate at the following skilled nursing facilities in California, which acquisitions were effective July 1, 2022: Premier Care Center of Palm Springs, a 99-bed skilled nursing facility located in Palm Springs, California, which is operated by an independent operating subsidiary of Ensign; Brookside Healthcare Center, a 97-bed skilled nursing facility located in Redlands, California, which is operated by an independent operating subsidiary of Ensign; and Broadway Villa Post Acute, a 138-bed skilled nursing facility located in Sonoma, California.

06:07 EDT Vertical Aerospace selects Molicel for VX4 aircraft battery cells - Vertical Aerospace announced a strategic partnership with E-One Moli Energy - Molicel -, a manufacturer of lithium-ion cells, to supply high power cylindrical cells for Vertical's VX4 eVTOL aircraft. Vertical has now secured the supply of market leading battery cells to develop the VX4 through to certification and entry into service, working with Molicel to increase supply as the VX4 is brought into mass production. The battery system will be certified concurrently with the European Union's Aviation Safety Agency and the UK's Civil Aviation Authority with Vertical targeting 2025 for entry into service.

06:05 EDT Ensign Group acquires five nursing facilities in Texas - The Ensign Group announced that it acquired the operations of the following skilled nursing facilities in Texas: The Eden of Las Colinas, a 118-bed skilled nursing facility, located in Irving, Texas; Pleasant Valley Healthcare and Rehabilitation Center, a 124-bed skilled nursing facility located in Garland, Texas; Millbrook Healthcare and Rehabilitation Center, a 124-bed skilled nursing facility in Lancaster, Texas; McKinney Healthcare and Rehabilitation Center, a 125-bed skilled nursing facility in McKinney, Texas; and Park Manor Bee Cave, a 140-bed skilled nursing facility in Bee Cave, Texas. The acquisitions were effective July 1, 2022. The acquisition of The Eden of Las Colinas also includes the real estate at the facility, which was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign's captive real estate company. The four other acquisitions will be subject to a long-term, triple net lease.

06:03 EDT Ensign Group acquires healthcare campus in Arizona - The Ensign Group announced that it acquired the real estate and operations of Villa Maria Post Acute and Rehabilitation, a 65-bed skilled nursing facility, Villa Maria Wellness Living, a 31-bed assisted living facility and Tucson Recovery at Villa Maria, a 30-bed behavioral health unit, each located in Tucson, Arizona. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign's captive real estate company, and the acquisition was effective July 1, 2022. In separate transactions on the same day, Ensign announced that in addition to Villa Maria, Standard Bearer also added four new real estate assets, one of which also included new operations, as follows: the real estate and operations of The Eden of Las Colinas, a 118-bed skilled nursing facility, located in Irving, Texas; and the real estate of Premier Care Center of Palm Springs, a 99-bed skilled nursing facility located in Palm Springs, California, Brookside Healthcare Center, a 97-bed skilled nursing facility located in Redlands, California, and Broadway Villa Post Acute, a 138-bed skilled nursing facility located in Sonoma, California, each of which is operated by an independent operating subsidiary of Ensign. Also on the same day, Ensign announced that its affiliates entered into new long-term leases on five new operations, including the following: the operations of Henderson Health and Rehabilitation, a skilled nursing facility with 266 skilled nursing beds, located in Henderson, Nevada; and the operations of Pleasant Valley Healthcare and Rehabilitation Center, a 124-bed skilled nursing facility located in Garland, Texas, Millbrook Healthcare and Rehabilitation Center, a 124-bed skilled nursing facility in Lancaster, Texas, McKinney Healthcare and Rehabilitation Center, a 125-bed skilled nursing facility in McKinney, Texas, and Park Manor Bee Cave, a 140-bed skilled nursing facility in Bee Cave, Texas. All of these acquisitions were also effective July 1, 2022 and bring Ensign's growing portfolio to 258 healthcare operations, 26 of which also include senior living operations, across thirteen states. Ensign subsidiaries, including Standard Bearer, now owns 105 real estate assets.

05:49 EDT Amazon to take stake in Grubhub as part of Just Eat Takeaway.com agreement

05:48 EDT Just Eat Takeaway.com, Amazon enter into commercial agreement in the U.S. - Just Eat Takeaway.com N.V. (TKAYY) said it has entered into a commercial agreement with Amazon.com Services LLC (AMZN) in the United States. "Starting today, Amazon Prime members in the United States can sign up for a free, one-year Grubhub+ membership and access unlimited $0 delivery fees from hundreds of thousands of restaurants on Grubhub throughout the year. In addition to $0 delivery on eligible orders, Grubhub+ members get access to member-only perks and rewards." The agreement is expected to expand membership to Grubhub+, while having a neutral impact on Grubhub's 2022 earnings and cash flow, and be earnings and cash flow accretive for Grubhub from 2023 onwards, Just Eat Takeaway.com said in a statement. The commercial agreement automatically renews each year unless terminated by Amazon or Grubhub in accordance with the provisions of the commercial agreement. Under the commercial agreement, a subsidiary of Amazon will receive warrants over 2% of Grubhub's fully-diluted common equity. Amazon will also receive warrants over up to a further 13% of Grubhub's fully-diluted common equity, the vesting of which is subject to the satisfaction of certain performance conditions, principally the number of new consumers delivered through the commercial agreement. The commercial agreement with Amazon constitutes a Class 2 transaction under the UK Financial Conduct Authority Listing Rules.

05:18 EDT Genentech announces FDA acceptance of mosunetuzumab BLA - Genentech, a member of Roche, announced that the FDA has accepted the company's biologics license application, or BLA, and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory, or R/R, follicular lymphoma, or FL, who have received at least two prior systemic therapies. FL is the most common indolent form of non-Hodgkin's lymphoma, or NHL, a type of blood cancer, which often returns after initial therapy. The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29.

05:11 EDT BiomX announces voluntarily delisting of stock from trading on TASE - BiomX announced that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange, or TASE. Based upon a review of the recent trading volume of BiomX's common stock on the TASE and the costs associated with maintaining a presence on more than one stock exchange, BiomX's management and its board of directors have concluded that it would be in the best interests of shareholders to have BiomX's common stock listed on a single stock exchange. Under applicable Israeli law, the delisting of BiomX's shares of common stock from trading on the TASE is expected to become effective in three months, on October 6. During this time, BiomX's shares will continue to be traded on the TASE. Following the delisting of BiomX's shares of common stock on the TASE, BiomX's shares will continue to be listed on the NYSE American and all BiomX shares now traded on the TASE are expected to be transferred to the NYSE American where they can continue to be traded.

05:06 EDT Amazon announces new deals for Prime members ahead of Prime Day - The company said, "Ahead of Prime's biggest savings event exclusively for members, Prime Day on July 12-13, Amazon announced new offers and experiences exclusively for members. Starting today, Prime members in the U.S. can enjoy a free, one-year Grubhub+ membership with no food-delivery fees on eligible orders. Members can use this new perk in more than 4,000 cities with hundreds of thousands of restaurants across the country when ordering on Grubhub. Amazon is also announcing exciting, exclusive Prime member content for The Lord of the Rings: The Rings of Power. Additionally, Amazon is also unveiling exclusive deals for Prime members ahead of Thursday Night Football's anticipated launch, as well as exclusive experiences for members at the upcoming Ultimate Crown streamers vs. gamers battle featuring MrBeast and Ninja. In anticipation of Prime Video's most eagerly awaited new series launching on September 2, The Lord of the Rings: The Rings of Power, Prime members globally can enjoy 48-hour advance access to a never-before-seen 60-second exclusive sneak peek starting today. This week, Amazon also surprised lucky Prime members from around the world with an opportunity to attend the London Global Premiere of The Lord of the Rings: The Rings of Power in August. Ahead of the first exclusive Thursday Night Football game kicking off on Prime Video on September 15, Amazon is offering members Prime Day savings a week early. Exclusive deals range from home entertainment devices, like Fire TV smart TVs, to fan gear for members to prepare their living rooms and get ready for game day."

05:02 EDT Light & Wonder announces agreement between OpenBet, Sazkabet - Light & Wonder announced that its sports betting business has successfully delivered its platform to Sazka a.s. and its Czech-facing sportsbook brand, Sazkabet. Sazkabet has entrusted OpenBet to power the next generation of its online and mobile sportsbook offering as part of a new agreement. Sazkabet has deployed the fully managed OpenBet platform, which includes the betting engine and a full risk and liability management pricing and trading service covering a wide range of sports. OpenBet is fully compliant for the Czech Republic market and will provide a safe and responsible betting experience. Sazka a.s. is the largest lottery operator in the Czech Republic.